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Herpesviruses are widespread and can infect both human and animals. The family 
Herpesviridae is subdivided into one unassigned genus and three subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae based on virus structure, 
host range and the capability to establish latency in the infected cells [1]. Although viruses of 
the family Herpesviridae can cause primary lytic infection in the infected host, lifelong latency 
is common in the infection caused by these viruses [2].  
1.1 Betaherpesvirinae 
Members of this subfamily share common characteristics:  a narrow cell spectrum of infection, 
relatively slow replication and they establish latency at the hematopoietic progenitor cells and 
monocytes [1]. Human cytomegalovirus (HCMV) and roseolovirus subtypes (HHV-6A, HHV-
6B, and HHV-7) are the main members of the human Betaherpesvirinae subfamily. Although 
infection by roseoloviruses is always asymptomatic in healthy adults, they constitute an 
important health concern in neonates and infants. Moreover, roseoloviruses cause severe 
diseases such as encephalitis in immunosuppressed patients. [3-6]. HHV-6 can be a risk factor 
for multiple sclerosis and other neuroinflammatory conditions [7]. Importantly, HCMV is a 
very common pathogen worldwide with infection prevalence depends on socio-economic 
parameters. In developed countries, HCMV has a seroprevalence of 50-70%  [8, 9]. 
1.2 Human Cytomegalovirus (HCMV) 
Cytomegaloviruses (CMVs) are highly species-specific [1]. HCMV can be transmitted through 
saliva, blood transfusions, sexual contact, transplants, breast milk and across the placenta [10]. 
HCMV has the ability to infect a variety of different host cells including fibroblasts, epithelial 
and endothelial cells, monocytes, hepatocytes, smooth muscle cells, macrophages and neuronal 
cells [11, 12]. Although HCMV infection is usually asymptotic in healthy individuals [13],  it  
has serious life threatening complications such as retinitis, encephalitis, pneumonia, nephritis 
or gastroenteritis in immunosuppressed people, especially acquired immune deficiency 
syndrome (AIDS) or transplant patients [12, 14]. Moreover,  HCMV is one of the major causes 





1.2.1 General features of HCMV  
1.2.1.1 HCMV structure  
HCMV is one of largest viruses with a diameter of 150 to 200 nm and shares the highly 
characteristic herpesviruses structure [1, 16]. HCMV virion is composed of DNA, 

















Figure 1. Schematic illustration of HCMV. HCMV has a relatively large genome of approximately 
230 kbp located in the nucleocapsid which is embedded in the protein-rich matrix. The outer layer is a 
lipid envelope which contains the viral entry glycoproteins. Modified from John Paul Tomtishen III, 
2012 [18]. 
 
The mature infectious HCMV virion contains a double-stranded linear DNA core, which is 
located in an icosahedral nucleocapsid (90 to 130 nm in diameter), enveloped by a 
proteinaceous matrix (the tegument) [1, 16]. The tegument is an electron-dense matrix, which 
consists of a protein mixture of up to twenty components. The viral protein pp65 represents the 
main tegument component and it has immunodominant properties which drive the major 
immune-specific responses [18, 19]. The pp65 protein has several roles, mainly it promotes the 
development of virions and assembly of virus particles into the tegument [18].  Moreover, it 
facilitates the viral evasion of the host innate and adaptive immune compartments [20, 21]. 
Another important tegument protein is pp71, which regulates the expression of immediate early 
proteins [18]. 
The envelope of HCMV consists of a double lipid membrane, in which several highly conserved 
glycoproteins are incorporated such as gB, gH and gL [22]. These glycoproteins allow receptor 




of virus neutralizing antibodies [24, 25]. The glycoprotein gB has a role as virus fusogen, which 
is triggered by gH/gL complexes [26-28]. The glycoproteins gH and gL form a trimer complex 
with gO (gH/gL/gO) which facilitates virus entry into all cell types while a pentamer complex 
of gH/gL with other viral proteins (gH/gL/UL128/UL130/UL131) is required for entry into 
epithelial and endothelial cells but is dispensable for infection of fibroblasts [29-35].  
1.2.1.2 HCMV genome 
HCMV has one of the largest genomes of all herpesviruses. Nevertheless, HCMV has a typical 
herpesvirus genome structure with unique long (UL), unique short (US), and repeat regions. 
Since each long and short region can be oriented in either direction, four genome isomers are 
produced during replication (Class E genome) (Figure 2). The UL and US regions are both 
flanked by a pair of inverted repeats; terminal repeat long/internal repeat long (TRL/IRL) and 
internal repeat short/terminal repeat short (IRS/TRS) (Figure 2) [1, 36]. 
Figure 2. Schematic diagram of HCMV genome. The US and UL regions can be arranged in different 
ways resulting in four different isomers. Modified from  Fields Virology, 2013 [1].  
The laboratory HCMV strain AD169 genome is composed of 229354 bp which encodes 208 
open reading frames (ORFs) of 100 or more amino acids [37]. These ORFs are numbered 
sequentially according to their location within the unique (US and UL) and the repeated regions 
[37, 38]. In contrast to the laboratory strain AD169, additional ORFs have been identified and 




AD169 has been extensively passaged in cell culture, and has lost a large number of genes in 
the UL/b' region of the genome, as well as elsewhere in the genome [39, 40].  
Genomic and proteomic analysis has shown that HCMV shares more than 40 ORFs with high 
homology to proteins encoded by alpha- and gamma- herpesviruses which provides an evidence 
of a common origin of the three subfamilies [1]. About 25% of HCMV ORFs encode proteins 
involved in viral DNA metabolism and replication, while the other 75% are involved in the 
maturation, structural organization of virions and other viral-mediated functions and 
pathogenesis such as immune evasion [1, 38]. The ORFs-encoded proteins in UL regions are 
mainly involved in DNA replication and repair or in virion structure. They are grouped in seven 
conserved gene blocks (A–G) which are also found in other herpesviruses genomes, however, 
they exist in a different order in the alpha- and gamma- herpesviruses. On the other hand, the 
US ORFs or other ORFs encoded within the repeated regions of the HCMV genome are less 
well conserved compared to other herpesviruses [37, 42]. Analysis of wild type strains and 
genetically modified viruses encoding mutations of different ORFs showed that more than 50 
ORFs-encoding proteins are not essential for viral replication in vitro. However, these ORFs-
encode proteins involved in viral growth in vivo , pathogenesis, and evasion of  the host immune 
system [38, 43]. 
Like other herpesviruses, HCMV can establish lytic infection and latency with intermittent 
reactivation and shedding of infectious virions. HCMV has three overlapping phases in the 
productive lytic infection cycles. In these phases, HCMV replicates and infectious virions are 
eventually released from the infected cells. These phases are immediate-early (IE) (the first two 
hours) in which CD8+ T lymphocytes (CTLs) are directed against IE-1 transcription factor, 
however that can be selectively blocked  by kinase activity of tegument protein pp65 [21, 44], 
delayed early (E) phase (the first 24 hours) and the late (L) phase (after 24 hours) [45]. HCMV 
IE gene products are required to initiate the expression of E genes. Consequently, The proteins 
of the E phase are then needed for the expression of L genes [46]. 
During HCMV latency, the virus stays dormant within the host cell without replication. HCMV 
reactivation from latency can cause severe multi-organ damage in congenitally infected 
newborns and individuals with deficient immune system such as organ transplant patients [47-
51]. The factors responsible for the persistence of viral genome in infected cells during latency 




1.2.2 Host defense and HCMV-encoded immune evasion 
An intact adaptive immune response is required to control HCMV replication during primary 
infection and reactivation. However, the innate immunity contributes to host defense against 
HCMV and adaptive immunity priming [14].  
In order to establish latency, HCMV has evolved numerous intriguing strategies to subvert the 
host immune defense and prevent its elimination from the human cells [53, 54]. More than 40 
HCMV gene products are recognized to have a role in modulating the host immune response 
following the viral infection [54]. As virus clearance is mainly dependant on cell-mediated 
immunity, which is mediated by CTLs and natural killer (NK) cells [55], HCMV encodes a set 
of proteins to efficiently escape from both cell types [54].  
1.2.2.1 Adaptive immune response 
1.2.2.1.1 Cell-mediated immunity 
The viral antigens are normally processed and presented by major histocompatibility complex 
(MHC) class I (MHC-I) molecules on the surface of infected cells [56]. The classical MHC-I 
molecules are also expressed as human leukocyte antigen (HLA -A, -B and -C alleles) [57]. 
CMV-specific CTLs recognizing peptides loaded on MHC-I molecules play a crucial role in 
antiviral-immune responses and recovery from primary CMV infection [53, 54]. In animals, 
suppression of CTLs causes reactivation and dissemination of latent CMV infection [58]. 
Specific CTLs against structural and non-structural viral proteins were identified in HCMV 
infections [59]. HCMV-specific CTLs for pp65 or IE1 showed higher proliferation than those 
specific for gB or other viral envelope proteins. These findings suggest pp65 and IE1 are the 
main targets for the CTL-mediated immune response [60-62]. However, It has been 
demonstrated that HCMV can interfere with antigen presentation by MHC-I molecules which 
stimulates specific CTLs [53]. Till now, HCMV is known to encode four immune evasion 
protein (US2, US3, US6 and US11) which are implicated in evading MHC-I antigen 
presentation [54]. The assembly of MHC-I molecules with peptides requires the interaction of 
a multi-protein complex in the endoplasmic reticulum (ER). Tapasin protein forms a protein 
complex through interaction with both the transporter associated with antigen processing (TAP) 
and MHC- I molecules, this interaction is required for peptide loading [63]. US3 retains MHC-
I molecules within the ER by inhibiting the interaction of tapasin with TAP [64, 65]. 




US6 associates with TAP which results in stabilization of a confirmation in TAP1 and therefore 
inhibits ATP binding and peptide translocation [66]. Moreover, HCMV encodes two other 
proteins that facilitate MHC-I heavy chain proteasomal degradation in HCMV-infected cells. 
US2 and US11 cause newly synthesized MHC-I molecules to be ubiquitinated which results in 
their degradation by the proteasome [67, 68]. Other cellular proteins such as Derlin-1 and 
SEL1L are essentially required for US11-mediated MHC-I degradation, while signal peptide 
peptidase is critical for US2 function [69-71].  
On the other hand, CD4+ T cells play a key role in initiating and sustaining the viral-specific 
immunity through priming CTL-specific immunity and guiding the naïve B cells to become 
plasma cells that are able to secrete viral specific antibodies [72-74]. The investigation of 
lymphocyte proliferation in HCMV-seropositive but immunocompetent adults showed a high 
frequency of CD4+ T cells that are specific for MHC class II (MHC-II)-presented viral peptides 
derived from HCMV proteins such as gB, gH, pp65, and IE proteins [75]. Moreover, CD4+ T 
cells are important for the suppression of CMV lytic infection [76, 77]. In MCMV infection, 
CD4+ T cells  play an important role in controlling primary infection in long term CTL-depleted 
mice [78]. In healthy HCMV-infected children, prolonged HCMV salivary shedding was 
associated with persistent deficiency of HCMV-specific CD4+ T cells immunity [79]. In order 
to subvert CD4+ T cells-mediated immune response, HCMV US2-encoded protein plays 
another role in immune evasion by downregulating MHC-II molecules. US2 targets the HLA-
DR- and HLA-DM-α chains for cellular degradation and therefore blocks antigen presentation 
to CD4+ T cells [80, 81]. 
1.2.2.1.2 Humoral adaptive immunity 
Neutralizing antibodies play the main role for vaccine-induced protection against viral 
infections [82]. HCMV-infected immunocompetent individuals show high level of HCMV-
specific immunoglobulin (Ig)M antibodies upon primary infection which lasts for 3–4 months. 
After a few weeks, HCMV-specific IgG antibodies develop and persist for lifelong and the main 
protective antibody was found to be against viral gB [83]. In animals, the gB-specific antibodies 
could protect mice and guinea pig from lethal CMV challenges [84, 85].  
Several studies have been performed to evaluate the ability of gB administration to drive a 
strong and protective antibody response in humans [84, 86]. Nevertheless, the administration 




produce high protective antibodies titre that react with the surface of the virion and infected 
cells. Thus, there is yet no approved protective HCMV vaccine. [87]. Anti-gH antibodies also 
have a potent and complement-independent neutralizing activity [88, 89]. Other viral proteins 
such as pp65 (UL83), and pp150 (UL32) can also drive strong and long lasting antibody 
responses [90]. Other HCMV vaccine trials demonstrated that several viral proteins are 
recognized by humoral immunity and a protective response could be derived by the 
administration of attenuated HCMV strain Towne or passive immunisation with high-titer anti-
HCMV immunoglobulins [87].  
1.2.2.2 Innate immune response 
The NK cells play an important role together with CTLs for host defense with memory-like 
immune responses [91]. In mouse models, NK cells play a crucial role in MCMV clearance 
[92, 93]. Moreover, adoptive transfer of NK cells can protect mice against MCMV infection 
[94]. In humans, the importance of NK cells in the control of HCMV infection has been 
observed in NK cells-deficient patients [95-97]. However, HCMV encodes several proteins that 
block NK-mediated immune defense [95].  
HLA-E is a non classical MHC-I molecule which is expressed in variety of cells including 
monocytes and macrophages and it plays an important role in controlling NK cells function. 
HLA-E binds to NK receptor (CD94/NKG2A) resulting in inhibition of NK-mediated immunity 
[98-100]. The signal sequence of HCMV UL40 gene product is a canonical ligand for HLA-E 
and negatively regulates NK cells [101]. Moreover, HCMV-encoded UL141 protein 
downregulates the NK-activating ligand CD155, which results in further suppression of NK-
mediated immunity [102]. Furthermore, the HCMV UL18 gene encodes a protein homolog to 
MHC-I which impairs NK-mediated cell lysis [103]. 
Taken together, there are numerous HCMV-encoded proteins that interfere with antiviral innate 
and immune and adaptive immune responses in addition to those mentioned in the previous 
paragraphs. The gene product of HCMV UL83 (pp65) inhibits the proteasomal processing of 
the immunogenic HCMV IE1 protein by phosphorylation [21, 54]. Moreover, the tegument 
UL82 protein (pp71) and US9 protein impair the antiviral immune response through inhibition 
of stimulator of interferon genes (STING) signaling [104, 105]. Additionally, HCMV encodes 
a homolog of human Interleukin-10 (hIL-10), which has a potent immunoregulatory function 




of these proteins (cmvIL-10) is 175 amino acids long and expressed during the late phase of 
lytic infection. The second isoform, which is called LAcmvIL-10, is shorter (139 amino acids) 
and expressed not only during lytic infection but also during latency [109, 110]. Similar to 
HCMV, the rhesus macaque CMV (RhCMV) UL111A also encodes viral IL-10 whereas 
MCMV lacks an IL-10 homolog [111]. cmvIL-10 mediates immune suppression of several 
effector immune cells and downregulates MHC-I and MHC-II in infected individuals [112]. 
Importantly, it interferes with dendritic cell (DC) function [108, 110, 113]. The main HCMV 
gene products involved in immune evasion are summarized in Table 1. 
HCMV gene product Mechanism of immune evasion References 
US2, US3, US6 and 
US11 




US2 and IE1  MHC-II downregulation and evasion of CD4+ T 
cells-mediated immunity. 
[80] 
US18 and US20 Evasion of NK-mediated immunity. [115] 
UL18 MHC-I homolog and evasion of NK cells. [53] 
UL16 NK cells function impairment. [80] 
UL40 Evasion of NK cells. [95] 
UL83 (pp65) Inhibition of IE1 proteasomal processing and 
inhibition of antiviral gene expression. 
[21, 54] 
IE2 Overexpression of anti-apoptotic FLIP protein.  [21, 80] 
UL82 (pp71) Inhibition of interferon-mediated immunity.  [104] 
UL111A (cmvIL-10) IL-10 homolog, modulation of MHC-I and MHC-




UL141 Downregulation of CD155. [53, 102] 
miR-UL112 Escape from NK-mediated immunity. [118] 
UL141- UL144 Inhibition NK-activating ligands. [53, 119] 
UL142 Suppression of NK- and CTL-mediated immunity. [80] 







1.2.3 HCMV and memory inflation 
Upon viral infection, specific T cells expand and proliferate in order to eliminate the infection. 
After viral clearance, only small population of specific T cells remain in blood and other 
compartments such as the bone marrow as memory T cells, the rest are eliminated by apoptosis 
[120]. However, during latent CMV infection in animals such as MCMV-infected mice, 
specific T cells recognizing CMV epitopes expand and proliferate and remain at high frequency 
with effector-memory phenotype [121-123]. It is hypothesized that during establishing 
persistent infection in healthy individuals, HCMV-specific CTLs are primed and boosted 
overtime by repetitive reactivation of HCMV which had been observed in cross-sectional 
studies [124-126]. However, memory inflation has not been proven yet in humans due to limited 
longitudinal studies [125]. The percentage of CMV-specific CTLs expand with time until 
becoming extraordinary large, with a size about 20% of total CTLs [123, 126-128]. 
Interestingly, these CTLs remain functional, non-exhausted and can even occupy up to 50% of 
the total memory compartment. They are maintained during the lifetime of the infected 
individual. Moreover, they show restricted contraction following priming with sustained 
“effector-memory” phenotype. This unique phenomenon is termed as memory inflation (Figure 
3) [123, 129-131]. In murine models, there was slight inflationary CD4+ T cells response post 
MCMV infection [132]. In humans, primary HCMV infection could also drive inflationary 
CD4+ T cells response in infected individuals [133]. 
  
Figure 3. Schematic diagram of Inflationary CTLs. During CMV infection inflationary CTLs expand 




1.2.3.1 Features of inflationary memory T cells 
Inflationary CTLs are characterized by an effector memory phenotype, in contrast to non-
inflationary T cells which typically have a central memory phenotype [130, 134]. Lymph node 
homing markers such as CD62L and CCR7 are expressed at a low level on inflationary memory 
CTLs [128]. Moreover, they express low levels of co-stimulatory receptors such as CD27 and 
CD28, but high level of inhibitory receptors such as CD85j which is a negative regulatory 
receptor that associated with aging of CTLs [122, 134-136]. Interestingly, they do not express 
inhibitory receptor PD-1, this feature may prevent the exhaustion of inflationary memory T 
cells  [128, 137].  
Inflationary memory CTLs remain proliferative and able to secrete effector cytokines such as 
IFN-γ and TNF-α and maintain cytotoxicity [138]. Moreover, they can respond to CMV 
reactivation or ex vivo stimulation [123]. This unique functional feature is characteristic for 
CMV-specific inflationary memory CTLs, while in cancer patients T cells are exhausted and 
are not capable of mediating cytotoxicity [137, 139]. Inflationary CMV-specific CTLs show 
restriction in T cell receptor (TCR) diversity which suggests that T cell populations have higher 
affinity to preferentially selected CMV epitopes which maintain their clonal selection and 
dominance [140, 141].  
1.2.3.2 Factors involved in memory inflation 
Although the main mechanisms explaining this phenomenon remain mysterious, some factors 
involved in memory inflation of CMV-specific CTLs will be here discussed [128].  
1.2.3.2.1 Antigen presentation 
It was suggested that viral antigen presentation by infected cells, which are accessible to the 
blood supply and CTLs, is one of the primary factors to drive memory inflation for MCMV  
[142].  Although HCMV harbors several genes involved in host immune evasion including 
those that downregulate MHC-I molecules (see Section 1.2.2), antigen processing and 
presentation by MHC-I is crucial for driving memory inflation that may be primed due to cross-
presentation by DCs [143-146]. Studies on MCMV showed that this inflationary response was 
facilitated  through antigen presentation by non-hematopoietic cells in the lymph nodes during 
the latent MCMV infection. These expanded CTLs subsequently move to peripheral tissues, 




1.2.3.2.2 Repetitive antigen exposure 
Repetitive antigen exposure is essential to establish memory inflation response. Murine models 
showed that the MCMV-specific CTLs failed to divide when transferred from MCMV-infected 
mice to uninfected ones [128]. Moreover, a low infective dose of MCMV curbed the 
proliferation and accumulation of inflationary CTLs [148]. 
1.2.3.2.3 Cytokines and co-stimulatory molecules 
It has been shown that secreted cytokines and co-stimulatory molecules play an important role 
in developing inflationary memory responses for CMV [149]. For example, the co-stimulatory 
4-1BB and OX40 molecules are expressed on CMV-specific CTLs after activation and they 
play a role in MCMV-driven memory inflation [150, 151]. Murine models showed also that the 
MCMV-driven memory inflation is dependent on autocrine secretion of interleukins such as 
IL-2 [152, 153].  In addition, it was suggested that other cytokines such IL-15 play a role in 
potentiation of CTL proliferation and driving inflationary memory responses for CMV [154]. 
1.2.4 CMV-based vaccines 
Interestingly, HCMV is able to superinfect individuals who were previously infected with 
another HCMV strain [155]. This fact is a major advantage of HCMV-based vaccines which 
makes them capable of infecting both HCMV-seronegative and seropositive individuals [156, 
157].  Moreover, the inflationary memory CTLs are not exhausted and can respond efficiently 
to antigen-presenting cells as previously described (see Section 1.2.3).  
It was demonstrated that recombinat CMV-based vaccines can drive robust T cell stimulation 
and proliferation against heterogenous antigens which were encoded in CMV vectors with 
mediating therapeutic and prophylactic responses [158-162]. 
1.2.4.1 Recombinant CMV vectors against infectious diseases 
Several studies have investigated prophylactic and therapeutic CMV-based vaccines against 
different infectious diseases such as simian immunodeficiency virus (SIV) [163, 164], 
Mycobacterium tuberculosis (TB) [161, 165] and Zaire ebolavirus (ZEBOV) [166].  
It is still unclear how CMV-based vaccines mediate their prophylactic and therapeutic effects. 




vaccines against  SIV in macaques and ZEBOV in mice [163, 166]. However, it could be also 
mediated by strong antibody-driven response which was previously shown in CMV-based 
vaccines against Ebola infection in macaques [162]. 
1.2.4.2 CMV-based vaccines for cancer therapy 
Noncommunicable diseases are responsible for the majority of natural deaths, accounting for 
about 86% of deaths in Europe [167]. Cancers are becoming increasingly prevalent and are 
expected to be the leading cause of death in the 21st century [168]. In 2015, there were more 
than 17 million incident cancer cases worldwide and about 8.7 million deaths due to cancer 
[169].  
The successful use of CMV-based vaccines against infectious diseases was expanded to 
develop CMV-based vaccines against cancer such as prostate cancer, melanoma and HPV-
induced canecr which could generate a pool of tumor specific CTLs that mediate anti-tumor 
prophylactic and therapeutic responses [170].  
1.2.4.2.1 CMV-based vaccines for prostate cancer therapy 
MCMV has been successfully used to generate a CMV-based vaccine encoding human 
prostate-specific antigen (PSA) to treat prostate cancer in mouse models. The recombinant 
MCMV expressing MHC-I-restricted human PSA epitope was able to drive inflationary CTLs 
responses against PSA in a mouse model. More than 85% of the immunized mice showed total 
clearance of PSA-expressing tumors [171]. 
1.2.4.2.2 CMV-based vaccines for melanoma treatment 
A single dose of recombinant MCMV expressing unmodified melanoma antigen tyrosinase-
related-protein (TRP)-2 showed prophylactic response and significant reduction of tumors in a 
melanoma mouse model [172]. Interestingly, this immune response was independent of CTLs, 
instead tumor-specific antibodies were involved in this anti-melanoma response [173] 
In another model using a MCMV-based vaccine expressing the melanoma antigen gp100, a 
tumor-associated self antigen, the vaccine failed to drive CTL tumor-specific responses. 
However,  recombinant MCMV vaccine expressing a modified gp100 antigen that was mutated 
for higher MHC-I affinity could induce tumor-specific CTL cytotoxicity when used as a 




1.3 Human papillomavirus (HPV)-induced cancer 
HPV is one of most common sexually transmitted diseases worldwide [176]. HPV causes 
transient infection that can develop into cancer [177]. A prophylactic vaccine has been 
generated with a high efficiency against high risk HPV strains such HPV16 and 18 [178]. HPV 
infection is usually cleared by the immune system in the immunocompetent, although the 
infected individuals remain at risk of developing lifelong infection which can progress to cancer 
[179, 180]. 
1.3.1 HPV epidemiology 
It has been demonstrated that more than 7-8% of all human cancers are associated with HPV 
[181]. Approximately 530,000 women develop cervical cancer worldwide each year with HPV 
being associated with more than 99% of these cases [182, 183]. In Europe, more than 58,000 
women are annually diagnosed with cervical cancer and more than 24,000 cases die because of 
this disease every year [184]. In the United States, more than 26,000 individuals were diagnosed 
with HPV-associated cancer per year between the years 2004 and 2008 [185]. Moreover, about 
4100 women die annually in the United States due to cervical cancer caused by HPV with the 
genotype HPV16 being the most implicated [186]. In addition to cervical cancer, HPV is 



























Figure 4. Representation of the percentage of HPV-associated cancers. Modified from Brianti et 
al., 2017 [177].  
 
1.3.2 General features of HPV 
HPV can infect epithelial cells resulting in transformation and tumor development due to the 
HPV-encoded oncoproteins [177]. HPV has an icosahedral capsid and harbours a double-
stranded circular DNA with about 8 kb genome size [188]. HPV encodes early genes (E-genes) 
involved in replication, transcription and transformation while late genes (L-genes) play a key 
role in capsid formation. HPV also harbors regulatory long control region (LCR) and a 
noncoding region [189]. Late HPV genes include the L1 and L2 genes that encode the proteins 
building the HPV capsid. The HPV capsid contains 72 pentameric capsomeres, each of them 
composed of five L1 and L2 proteins. HPV assembles in the nucleus of the infected cells with 
incorporation of L1 and L2 into virus-like particles [179, 190, 191].  
The HPV-encoded E6 and E7 are the main conserved oncogenes and can integrate into the 
genome of infected cells [192]. This step is crucial towards alteration of cell cycle regulation, 
telomerase maintenance and blocking of tumor suppressor pathways which results in malignant 
transformation and cancer initiation [193]. The transformed epithelial cells process and present 
epitopes of both E6 and E7 proteins [194]. High-risk HPVs are of different genus (Alpha, Beta 
and Mu) (Figure 5).  However, the members of the α-genus have been extensively studied due 
to their high prevalence including HPV16 and 18 genotypes, which account for over than 70% 





Figure 5. Schematic illustration of high-risk HPV genome. HPV encodes late structural genes 
(orange), early genes (green) and oncogenes (red). Modified from Doorbar et al., 2015 [195]. 
High-risk HPV-encoded E6 consists of 158 amino acids. E6 promotes cancer initiation and 
proliferation by interacting with the tumor suppressor p53 protein which is mediated by a 
trimeric complex formation of E6, p53 and ubiquitination enzyme E6-AP [192]. This 
interaction blocks the action of p53, which leads cell growth and tumor formation [197, 198]. 
Additionally, HPV16-encoded E7 binds with high affinity to cellular retinoblastoma protein 
(pRb). The Rb protein has a negative cell-cycle regulatory function in the G1/S as well as G2/M 
transitions [192]. The Rb protein mediates its function by binding to E2F-family transcription 
factors, which in turn represses the expression of enzyme genes involved in cell replication. E7 
protein binds to specific region of Rb protein called pocket domains. These pocket domains of 
Rb protein are the functional domains for the protein-mediated tumor suppressor function. The 
binding of E7 with Rb protein alters the Rb-E2F interaction and consequently resulting in E2F 
release in the active form. The transcriptionally active form of E2F stimulates cell division and 






Figure 6. Mechanism of action of HPV16-encoded oncoproteins. HPV16-encoded E6 and E7 interact 
with p53 and Rb proteins, respectively, which leads to initiation and progression of cancer in HPV-
infected cells. Modified from Yim and Park, 2005 [192].  
 
Despite highly effective prophylactic vaccines, there is no approved therapeutic vaccine that 
triggers cell-mediated immunity against HPV-induced cancer [202]. Although individuals are 
protected if they are vaccinated prior to the virus exposure, the unvaccinated population will 
remain at risk lifelong of developing cervical and other related cancers [203]. MCMV was 
utilized to generate recombinant viruses that express epitopes derived from E7 protein. These 
MCMV-based vaccines induced robust tumor-specific CTLs that were able to protect the mice 
from tumor grwoth. It was also demonstrated that fusing a single HPV E7-derived epitope to 
the C-terminal of viral proteins is crucial to generate MHC-I-restricted CTLs recognizing this 
epitope [204, 205].  
1.4 Glioblastoma multiforme (GBM) 
The glial cells play the main role in supporting and isolating neurons. Moreover, they have an 
important role in the functional signal processing of the CNS and in the maintenance of 
homeostasis and brain metabolism  [206]. Gliomas are the most common primary tumors of the 
central nervous system (CNS) [207]. The name refers to its neuroepithelial tissue of origin, the 
glial cells. The recent World Health Organization (WHO) classification updated in 2016, 




The low-grade gliomas (WHO I and II) show a comparatively good cell differentiation, and 
thus a high morphological similarity with glial cells [207]. Low-grade malignant gliomas often 
have a long clinical course due to their rather slow progression [209]. A distinction is made 
between higher-grade neoplasia, so-called the high-grade gliomas (WHO III and IV). WHO III 
tumors are characterized by increased cytologic anaplastic signs with increased proliferation 
rate, diffuse infiltrative growth pattern and developing perifocal edema. Glioblastoma 
multiforme (GBM), the most common malignant tumor of glial cells, is classified as the most 
aggressive glioma (WHO IV) which shows additional malignant characteristics such as 
neoangiogenesis and tumor necrosis [210].  
GBM is one of the most aggressive cancers, with median survival of only 14-months after 
diagnosis [211-213]. The most commonly used treatment options are ineffective for GBM 
therapy, although different drug combinations have been investigated [214, 215]. Relapse 
usually occurs, which can no longer be treated and leads to death after a short time period [216, 
217]. The fact that GBM is incurable, underlines the need to develop new approaches for the 
therapy of GBM. To date, the most promising therapeutic strategies for GBM treatment are 
immunotherapy-based approaches [218].  
1.4.1 Incidence of GBM 
GBM accounts for about 16% of all CNS tumors and 54% of malignant tumors in the CNS 
[219]. Every year, there are more than 12,000 new cases diagnosed with GBM in the United 
States [220]. According to Central Brain Tumor Registry of the United States (CBTRUS) 
report, the incidence of GBM in the United States is 3.19 per 100,000 individuals. The median 
age of people with GBM is 64 years. The incidence increases with age and reaches its maximum 
at 15.27 per 100,000 in the age group 75-84 years [207, 212].  
Despite modern therapy concepts, the survival prognosis of GBM patients is severely limited 
[207, 221]. In the total population, the average 1-year survival is about 40.8%, while the 5-year 
survival is about 6.8% ,and the 10-year survival is only 0.71% [207, 222]. 
 
1.4.2 Pathology of GBM 
Recently, it has been established that GBM originates from neural stem cells within 
subventricular brain zone [223]. The diagnosis of GBM is mainly dependent on the observation 




[223, 224].  Although GBM is of one most of aggressive cancer types (Figure 7), it rarely 
metastasizes outside the CNS [225]. Recent studies showed synaptic and electrical integration 
among glioma and neural cells which promotes glioma progression [226]. 
1.4.3 Standard GBM treatment strategies 
The current gold standard “maximum” therapy consists of tumor resection, followed by 
combined chemo-radiotherapy. Patients treated with this regimen have a median survival time 
of about 14 months [221, 227].  GBM almost always relapses near the surgical margins and 
becomes resistant to therapy [214].  
 1.4.4 GBM-induced immunosuppression  
GBM is characterized by immunosuppression in the “cold” local tumor microenvironment 
(TME). There is high predominance of CD11b+ myeloid cells including brain‐resident 
microglia and myeloid‐derived suppressor cells (MDSC), which have immunosuppressive 
characteristics such as producing IL‐10 and tumor growth factor beta (TGF-β) [228-230]. 
Moreover, the T‐cell checkpoint molecule PD-L1 is highly expressed in patients’ GBM tissue 
[231]. Immunotherapy is one of the promising approaches for GBM therapy by converting the 
TME from “cold” to “hot” with improved immune response [232].     
Moreover, GBM tumors are also able to induce systemic immunosuppression. GBM patients 
have higher level of MDSC cells in the blood than normal individuals and have elevated serum 
levels of IL-10. Additionally, circulating monocytes show higher level of PD-L1 expression. In 
addition, circulating T cells are limited in number and impaired in function as well [233, 234]. 
The clinical use of PD-1/PD-L1 checkpoint blockades did not offer any survival advantage in 
GBM patients because GBM shows poor responses to immunotherapies that have been 
successful in more immunogenic cancers due to immunosuppressive TME [235].  
1.4.5 HCMV infection of GBM cells 
The relationship between HCMV and GBM tumors has been extensively studied. The detection 
of HCMV antigens and nucleic acid in GBM cells suggests that HCMV may be implicated in 
the tumor initiation and malignancy [236, 237], however, HCMV was not detectable in the 
surrounding tissues [236]. On the other side, HCMV has the ability to reduce the viability of 




GBM cells with HCMV did not show any increase in resistance to chemotherapeutic drugs 
[238]. 
Interestingly, HCMV antigens of HCMV-positive GBM clinical samples were recognized and 
killed by autologous HCMV-specific CTLs [239]. This is why infecting GBM tumors with 
HCMV-based vaccines expressing several antigens, which are entirely absent in the tumors, 
may drive polyclonal CTLs and could be considered as a novel approach for GBM therapy. 
   
 
Figure 7. Magnetic resonance imaging (MRI) of brain.  (A) The image of MRI does not show any 
brain pathology. (B) The MRI scan shows a brain tumor in the posterior part of the right frontal lobe 













1.5 Project outline 
After HCMV infection, T cells with high avidity for dominant viral antigens are generated and 
maintained at high frequencies. These cells show a characteristic effector-memory phenotype 
and lack features of T cell exhaustion. This phenomenon has been called memory inflation and 
was originally discovered in animal models of CMV infection. Based on this unique feature, 
HCMV represents a promising vector for the construction of recombinant vaccines that express 
heterologous (non-HCMV) proteins that are not normally expressed by HCMV wild type (WT). 
These neoantigens can be subsequently processed and presented (neoepitope). The 
heterologous proteins should elicit an equally powerful T cell response that could then be 
exploited for vaccination against chronic infectious disease such as HIV or cancer 
immunotherapy. Although several studies were carried out in the last few years aiming to 
develop therapeutic and prophylactic vaccines based on animal CMVs, there is no published 
study yet for HCMV-based vaccines.  
1.3.1 Objectives 
HPV16-encoded E6 and E7 are the principle conserved oncogenes responsible for cell 
transformation and carcinogenesis. Despite the presence of prophylactic vaccines, there is no 
approved therapeutic vaccine for HPV-induced cancer although different strategies have been 
attempted. Moreover, we investigated the use of HCMV-based therapeutic viral vaccines to 
drive the autologous immune system for elimination of tumor cells. GBM cells are permissive 
to HCMV, thus they can be antigenic and act as a target for CTLs upon HCMV infection 
through expression and presentation of a neoepitope.  
In this study, we aimed to: 
A. Develop therapeutic HCMV-based vaccines against HPV-induced cancer and GBM 
using two different HCMV strains (Merlin and TB40/E) 
B. Investigate the functionality of HCMV-based vaccine to stimulate specific T cells in 
vitro. 








1.3.2 Technical approach 
A. Construction of HCMV-based therapeutic cancer vaccines 
1- HCMV vector modification and optimization 
We aimed to knockout MHC-I downregulating genes (US2-US11) using bacterial artificial 
chromosome (BAC) technology and recombineering to generate HCMV mutants with 
impaired immune evasion.  
2- HPV antigens expression and presentation 
HPV16 E6 and E7 proteins were our target antigens. An immunogenic E6/E7 fusion protein 
without transforming activity (E6/E7) was used in this study to generate HCMV-based 
vaccines expressing E6/E7 protein as a source of T cell epitopes. Moreover, another set of 
vaccines was constructed with an E6-derived single epitope fused to HCMV proteins. 
B. In vitro functional assays of HCMV-based therapeutic vaccines 
Primary T cells as well as T cell lines specific for HCMV-encoded epitope or neoepitope 
were generated by transduction with specific TCRs. HCMV-infected fibroblasts and GBM 
cells were investigated for their ability to stimulate these specific T cells. 




2. Materials and Methods 
2.1 Materials 
2.1.1 Primary cells, established cell lines and bacterial strains 
2.1.1.1 Primary cells are listed in Table 2 
Cells Feature Reference 
Fi301 Human embryonic fetal fibroblasts with HLA-
A2 haplotype. 
[241] 
Table 2. List of the primary cells. 
2.1.1.2 Cell lines are listed in Table 3 
Cells Feature Reference 
CaSki  Cervix cells; derived from metastatic 
site (small intestine) with HLA-A2 
haplotype. 
ATCC® CRL-1550™ 
HEK Human embryonic kidney cell line. ATCC® CRL-1573™ 
HEK293T  Human embryonic kidney derived 
from HEK cells. Transfected 
plasmid with SV40 origin of 
replication can replicate efficiently 
in HEK293T cells and maintained in 
a high copy number; which greatly 
increase the amount of recombinant 
protein or retrovirus that can be 
produced from the cells. 
ATCC® CRL-3216™ 
Jurkat E6.1 and Jurkat 76 
(J76) 
Human T cell lines derived from 
acute T cell leukemia.  
ATCC® TIB-152™ 
LN18  GBM cell line with HLA-A2 
haplotype. 
 ATCC ® CRL-2610™ 
U251 GBM cell line with HLA-A2 
haplotype. 
CVCL_4773 




U343 GBM cell line with HLA-A2 
haplotype. 
ATCC® HTB-17™ 
Table 3. List of the cell lines. 
2.1.1.3 Bacteria 
Laboratory strains of Escherichia coli (E. coli) were grown in Luria-Bertani (LB) medium (see 
Section 2.1.6.1) or plated on LB agar plates. The LB media and agar were sterilized by 
autoclaving. LB agar was supplemented with the appropriate antibiotics and poured into 10 cm 
diameter Petri dishes. Different antibiotics were used in this project, for example: ampicillin 
(amp) (100 µg/ml), kanamycin (kan) (50 µg/ml), and chloramphenicol (cam) (20 µg/ml). 
Bacteria were plated on LB agar by streaking with a wire loop and incubated overnight inverted 
at 32 oC or 37 oC. Single colonies were inoculated in sterile liquid LB medium supplemented 
with the appropriate antibiotics. Liquid cultures were incubated at 32 oC or 37 oC overnight in 
the bacterial incubator with shaking at 220 rpm.  Bacterial strains are listed in Table 4 
Name of bacteria Feature Reference 
GS1783 DH10B λcI857∆(cro-bioA)<>araC-P BAD, 
ISceI 
[242] 
NEB 10-beta E. coli A competent E. coli is a derivative of the 
popular DH10B. It is T1 phage resistant and 
endonuclease I (endA1) -deficient for high- 
quality plasmid preparations. 
New England Biolabs, 
Frankfurt, Germany  
Cat No. C3019H and 
C3019I 
Table 4. List of bacterial strains.  
2.1.2 Viruses and BACs 
2.1.2.1 Viruses 
HCMV viruses used in this project are listed in Table 5 
 
 




Virus name Feature Reference 
TB40/E HCMV strain TB40/E was derived from throat wash of 
a bone marrow transplant recipient by propagation for 





An enhanced green fluorescent protein (EGFP)-
expressing virus derived from TB40/E. The EGFP gene 
under the control of the viral major IE 
promoter/enhancer with a poly(A) site was introduced 
at an ectopic position downstream of US34A.  
[244] 
Table 5. List of HCMV viruses. 
2.1.2.1 BACs 
All modified HCMV and BACs used in this study are listed in Table 6 
BAC 
 
Derived virus Features Reference 
RCMV1161-BAC  HCMV BAC of Merlin strain with 
repaired RL13 and UL128 regions. 
It encodes an IRES-EGFP 
expression cassette which was 
inserted immediately downstream 
from UL122 (IE2). 
[245] 
TB40-BAC4  HCMV BAC of TB40/E strain. 
The mini-F sequence is replacing 


















RCMV1161 BAC with US2-3-6 
deletion. 
This work 


















RVTB40ΔUS11 with E6/E7 
protein expressed under the control 






RVTB40ΔUS11 with E6/E7 
protein expressed und the control 







RVTB40ΔUS11 with E6/E7 
protein expressed und the control 






RVTB40ΔUS11 with E6/E7 






RVTB40ΔUS11 with HPV16 E6-
derived peptide fused to C-






RVTB40ΔUS11 with HPV16 E6-











with HPV16 E6-derived fused to 
C-terminus of UL123 (IE1). 
This work 
Table 6. List of HCMV BACs.  
2.1.3 Chemicals and Reagents 
Chemicals and Reagents are listed in Table 7 
 
 





100bp DNA ladder Thermo Fisher Scientific, Braunschweig, 
Germany 
1kb DNA ladder 
Thermo Fisher Scientific, Braunschweig, 
Germany 
1kb DNA ladder GeneSTA Geneall, Seoul, South Korea 
Acetic acid (CH3COOH) VWR International, Darmstadt, Germany 
Agar-Agar (pure) Carl Roth, Karlsruhe, Germany 
Agarose-Standard Roti® grade Carl Roth, Karlsruhe, Germany 
Ammonium chloride Sigma-Aldrich, Steinheim, Germany 
Ampicillin sodium salt Carl Roth, Karlsruhe, Germany 
Bovine serum albumin (BSA) HyClone, South Logan, USA  
Bromophenol blue (C19H10Br4O5S) Sigma-Aldrich, Steinheim, Germany  
Chloramphenicol Carl Roth, Karlsruhe, Germany 
Citric acid Sigma-Aldrich, Steinheim, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany  
EDTA (ethylenediaminetetraacetic) Applichem, Darmstadt, Germany 
Ethanol absolute Applichem, Darmstadt, Germany 
Ethidium bromide 1% Carl Roth, Karlsruhe, Germany 
FACS clean BD, San Jose, USA 
FACS rinse BD, San Jose, USA 
G418 (Geneticin) 
Thermo Fisher Scientific, Braunschweig, 
Germany 
Glycerol Applichem, Darmstadt, Germany 
Human interleukin 2 (hIL-2)  Peprotech, Rocky Hill, NJ, USA 
Hydrochloric acid (37% HCl) Carl Roth, Karlsruhe, Germany 
Ionomycin Sigma-Aldrich, Steinheim, Germany  
Isopropyl alcohol (2-propanol) AppliChem, Darmstadt, Germany 
Kanamycin sulphate Carl Roth, Karlsruhe, Germany 
L-(+)- arabinose Sigma-Aldrich, Steinheim, Germany  
Lipofectamine 2000 Invitrogen, Karlsruhe, Germany 
Methanol VWR International, Darmstadt, Germany 
Opti-MEM I Invitrogen, Karlsruhe, Germany 




Phorbol myristate acetate Sigma-Aldrich, Steinheim, Germany  
Phosphate buffered saline (PBS) Santa Cruz Biotechnology, Heidelberg, 
Germany 
Polyethylenimine, Linear, MW 25,000 (PEI) Polysciences, Eppelheim, Germany 
Potassium acetate (KCH3CO2) Applichem, Darmstadt, Germany 
RNase A Sigma-Aldrich, Steinheim, Germany 
Roti®-Sep 1077 human Carl Roth, Karlsruhe, Germany 
Sodium acetate Applichem, Darmstadt, Germany 
Sodium chloride (NaCl) Applichem, Darmstadt, Germany 
Sodium hydroxide pellets, extra pure  Applichem, Darmstadt, Germany 
Sodium pyruvate  Biochrom AG, Berlin, Germany 
Tris Applichem, Darmstadt, Germany 
Tris-EDTA (TE) Sigma-Aldrich, Steinheim, Germany 
Trypan blue, 0.4% solution  Lonza, Cologne, Germany 
Trypsin/EDTA 0.05% 
Gibco, Thermo Fisher Scientific, 
Braunschweig, Germany 
Tryptone Carl Roth, Karlsruhe, Germany 
Water molecular biology grade Applichem, Darmstadt, Germany 
Yeast extract Carl Roth, Karlsruhe, Germany 
Table 7. List of chemicals and reagents. 
2.1.4 Consumables and equipment 
2.1.4.1. Consumables are listed in Table 8 
Consumables Supplier 
0.2 ml thin-walled PCR tube Applied Biosystems, Darmstadt, Germany 
BD Falcon 12 x 75 mm Tubes  BD, San Jose, USA 
Cell culture dish 50, 100 and 150 mm Sarstedt, Nümbrecht, Germany 
Cell culture plates Sarstedt, Nümbrecht, Germany 
Cell scraper Sarstedt, Nümbrecht, Germany 
Cell–culture flasks (T–25, T–75, and T-175) Sarstedt, Nümbrecht, Germany 
Cryotubes 1.8 ml Sarstedt, Nümbrecht, Germany 




Electroporation sterile cuvettes, 1 mm and 
2mm    
Biodeal, Markkleeberg, Germany 
 
Eppendorf tubes (1.5, 2ml) Sarstedt, Nümbrecht, Germany 
Falcon bacterial tubes (13ml) Sarstedt, Nümbrecht, Germany 
Falcon tubes (15 ml, 50 ml) BD, San Jose, USA 
Parafilm® M Bems, Neenah, Germany 
Pasteur pipette Sarstedt, Nümbrecht, Germany 
Petri dishes Sarstedt, Nümbrecht, Germany 
Pipette tips (1000, 200, 100 and 10) VWR International, Darmstadt, Germany 
Retronectin-coated plates Takara Bio, Otsu, Japan 
Sterile Pipettes (5, 10, 25 ml) Sarstedt, Nümbrecht, Germany 
Table 8. List of consumables. 
2.1.4.2. Equipment are listed in Table 9 
Equipment Supplier 
Analytical balance (Cubis MSA) Sartorius AG, Göttingen, Germany 
Bacterial incubators Classic Line Binder, Tuttlingen, Germany 
Centrifuges 5424/ 5424 R Eppendorf AG, Hamburg, Germany 
Cloning rings  Hilgenberg GmbH, Malsfeld, Germany 
CO2 tissue culture incubator (New 
Brunswick™ Galaxy® 170 R) 
Eppendorf AG, Hamburg, Germany 
Electrophoresis Power Supply (Power 
SourceTM300V) 
VWR International, Darmstadt, Germany 
FACScalibur Flow Cytometer - 4 Colors BD, San Jose, USA 
Flexcycler Thermocycler Analytik Jena, Jena, Germany 
Fluorescence inverted microscope Carl Zeiss MicroImaging, Jena, Germany 
Freezer -20 oC Kirsch, Willstätt, Germany 
Freezer –80 oC (HERA Freeze™ HFU B 
Series) 
Thermo Fisher Scientific, Braunschweig, 
Germany 
Fume cupboards (DELTAguard) Wesemann, Wangen im Allgäu, Germany. 




Laminar flow safety cabinet class II Bleymehl Reinraumtechnik, Inden, 
Germany 
Liquid nitrogen tank Air liquide, Düsseldorf, Germany 
Multiskan™ FC Microplate Photometer Thermo Fisher Scientific, Braunschweig, 
Germany 
Microscope (AE20) Motic, Wetzlar, Germany 
Microwave oven (R-201A) Sharp, Osaka, Japan 
Mr. Frosty™ Freezing Container  Thermo Fisher Scientific, Braunschweig, 
Germany 
Multiporator Eppendorf AG, Hamburg, Germany 
Nanodrop ND1000 PeqLab, Erlangen, Germany 
Neubauer cell counting chamber VWR International, Darmstadt, Germany 
Shaker bacterial incubator New Brunswick™ Innova, Edison, USA 
Orbital shaker (OS-10) PeqLab, Erlangen, Germany 
pH–meter (inoLab pH Level 1) Wissenschaftlich-Technische Werkstätten, 
Weilheim, Germany 
Pipetboy INTEGRA Biosciences AG, Biebertal, 
Germany 
Pipettes (single–channel, multichannel) VWR International, Darmstadt, Germany 
PTR-20 360 Degree Vertical Multi-Function 
Rotator 
Grant Bio, Shepreth, UK 
Spectrophotometer (Smart spec Plus) Bio-Rad, Feldkirchen, Germany 
Thermomixer  Eppendorf AG, Hamburg, Germany 
UV Transilluminator PeqLab, Erlangen, Germany 
Vortex Genie 2™ Bender&Hobein AG, Zurich, Switzerland 
Water bath Eppendorf AG, Hamburg, Germany 








2.1.5 Buffers and Gels 
2.1.5.1 DNA electrophoresis and electroporation buffers are listed in Table 10 
Buffer Composition 
1x PBS 9.55 gm from PBS powder 




40 mM Tris 
1 mM Na2EDTA.2H2O                   
20 mM acetic acid 99%,  
pH 8.0 
1 % agarose gel 
 
1 gm agarose                               
100 ml of 1x TAE buffer                                  
1 µl ethidium bromide 10 mg/ml    
hypo-osmolar buffer for eukaryotic cell 
electroporation 
Eppendorf AG, Hamburg, Germany 
Iso-osmolar buffer for eukaryotic cell 
electroporation 
Eppendorf AG, Hamburg, Germany 
6x DNA loading buffer 
 
0.2% bromophenol blue 
60% glycerol 
60 mM EDTA 












10 mM Tris HCl pH 7 
1 mM NaEDTA   
Table 11. List of plasmid and BAC DNA preparation buffers.  
2.1.6 Media preparation and composition 
2.1.6.1 Media and supplements for propagation of bacteria (E. coli) are listed in Table 12 
Media Composition 
LB medium (1X) 10 g tryptone           
5 g yeast extract      
10 g NaCl   
millipore water to 1L 
LB agar 10 g tryptone           
5 g yeast extract      
10 g NaCl   
15 gm agar 
millipore water to 1L 









2.1.6.2 Media and supplements for cultivation of mammalian cells 
2.1.6.2.1 Supplements are listed in Table 13 
Name Catalog No Company 
Fetal bovine serum (FBS) 11573397 Gibco, Thermo Fisher 
Scientific, Braunschweig, 
Germany  
L-alanyl-L-Glutamine K 0302 Biochrom AG, Berlin, 
Germany 
 
Minimum Essential Medium Eagle (MEM) F 0315 Biochrom AG, Berlin, 
Germany 
RPMI 1640 F 1215 Gibco, Thermo Fisher 
Scientific, Braunschweig, 
Germany 
Gentamycin-sulfate A 2712 Biochrom AG, Berlin, 
Germany 
Table 13. List of media supplements. 








Minimum essential Medium Eagle (MEM) 
10% heat inactivated FBS (hiFBS)   
2mM L-alanyl-L-glutamine 
50 μg/ml gentamicin 




PBMCs and Jurkat cell lines RPMI 1640 
2mM L-alanyl-L-glutamine 
10% hiFBS 
50 μg/ml gentamicin 





millipore water to 1L 
Table 14. List of cell culture media and buffers. 
2.1.7 Kits 
Kits used in this study are listed in Table 15 
Kit Supplier 
Basic NucleofectorTM kit for Primary 
Mammalian Fibroblasts 
Lonza, Cologne, Germany 
DNase I kit Promega, Walldorf, Germany 
GeneArt Life Technologies, Darmstadt, Germany 
GeneMATRIX Basic DNA Purification kit EURx, Gdańsk, Poland 
IFN-γ ELISA kit PeproTech, Hamburg, Germany 
NucleoBond® Xtra BAC MACHEREY-NAGEL, Düren, Germany 
NucleoBond® Xtra Midi MACHEREY-NAGEL, Düren, Germany 
OncoE6 Cervical Test™ kit Arbor Vita, CA, USA 
RecomWell HPV16/18/45 ELISA kit Mikrogen GmbH, Neuried, Germany 
RNeasy Plus Mini kit Qiagen, Hilden, Germany 
SuperScript III Reverse Transcriptase Invitrogen, Karlsruhe, Germany 
Table 15. List of kits. 
 





All enzymes used in this project were purchased from New England Biolabs, Frankfurt, 
Germany and are listed in Table 16 
Antarctic phosphatase (AP) KpnI 
BamHI NotI 
DpnI Phusion DNA polymerase 
EcoRI T4 DNA Ligase 
EcoRV Taq DNA polymerase 
Table 16. List of enzymes. 
2.1.9 Antibodies and peptides 
2.1.9.1 Antibodies 
All antibodies used in this project are listed in Table 17 
Antibody Supplier 
anti-CD28 (CD28.2) BioLegend, London, UK 
anti-CD3 (OKT3) BioLegend, London, UK 
anti- HLA-A*0201 antibody clone BB7.2 BioLegend, London, UK 
Table 17. List of antibodies. 
2.1.9.2 Peptides 
All peptides used in this project are purchased from Peptides&elephants GmbH, Hennigsdorf, 
Germany and listed in Table 18 
Peptide Sequence 
CMV pp65 (495- 503) NLVPMVATV 
HPV E6 (29-38) TIHDIILECV 
Table 18. List of peptides.  
 




2.1.10 Plasmids and vectors 
All plasmids and vectors used in this project are listed in Table 19 
Name Feature Reference 
GALV-env Gibbon ape leukemia virus (GALV) envelope-
encoding retroviral vector. 
[246] 
MLV-gag/pol Murine leukemia virus (MLV) gag/pol- 
encoding retroviral vector. 




pcDNA3.1(+) Mammalian expression vector; Catalog 
No.V790-20. 
Invitrogen 
pcDNAE6/E7Kpn-I pcDNA3.1(+) mammalian expression vector 
harboring fused consensus sequence of E6/E7 
at Kpn-I restriction site. 
This work 
 
pEF6/V5-His A Mammalian expression vector; Catalog #V961-
20. 
Invitrogen 
pEF6E6/E7EcoRI pEF6/V5-His A mammalian expression vector 
harboring fused consensus sequence of E6/E7 
at EcoRI restriction site. 
This work 
pEPkan-S Mammalian expression vector that encodes the 
kanamycin cassette for mutagenesis. 
[242] 





pJetConE6E7 pJET1.2/blunt vector harboring fused 
consensus sequence of E6/E7. 
This work 
pMP71-PRE-E6 Retroviral vector harboring TCR (α and β) for 
HPV16 E6 with P2A linker. 
This work. 
Table 19. List of plasmids and vectors.  
 





All primers used in this project were designed using Vector NTI 9.1 software (Invitrogen), 
ordered and purchased from Integrated DNA Technologies (IDT, Leuven, Belgium). 
Sequencing reactions were performed by LGC Genomics GmbH, Berlin, Germany (Table 20). 
Primers Sequence (5`-3`) 

















Sequencing of MHC-I down regulating genes 
SeqUS2-3 F CTGCCAGTGCTCTCGCTCGAGCAC 
R CAAAAACACCGTGCAGTCCACACGC 
SeqUS6 F CCGGAGTTGTCTATCGCGACAT 
R ACAAATATATGGAGTTTGTGTAATGC 
SeqUS11 F CAGGCAGATCGCCAGAGGG 
R  TTCTATCACCTAATCTGTCGTACTGTC   















































SeqUL111 F ATGCTGTCGGTGATGGTCTC 
R TCGAGTGCAGATACTCTTCGAG 







SeqUL83 F AGTGGACGTGGGTTTTTATAGAGT 





UL83RT F GCAGAACCAGTGGAAAGAGC 
R GTGTCGGTACTCAAGCTTGC 
RT PCT primer for HPV16 E6 and E7 
E6RT F GATCCTGTTCCTGGTGGCC 
R CAGGTGTCTCTGCAGGGG 
E7RT F GACCTGCAGCCTGAGACC 
R GGGTTTCTGGGAGCAGATGG 







SeqIE1 F GAGGAGTGTTAGTAACCGCGA 
R AGCAGAGTGATGAGGAACAGG 











Table 20. List of primers. 
2.1.12 Software is listed in Table 21 
Name Manufacture 
BLAST NCBI, Bethesda 
EndNote X8 THOMSON  REUTERS 




FACStation Software version 3.4 BD Biosciences 
FinchTV 1.4.0 Geospiza, Inc. 
GraphPad Prism 8.1.0 GraphPad Software Inc. 
ND-1000 V.3.0.7 PeqLab 
Vector NTI Advance™ 9.1 Invitrogen 
Table 21. List of software. 
2.2 Methods 
2.2.1 Standard molecular biology methods  
2.2.1.1 Polymerase chain reaction (PCR) 
PCR was used to amplify gene sequences using complementary oligonucleotides, so-called 
primers. For routine PCR, HotstarTaq polymerase (polymerase of the thermophilic eubacterium 
Thermus aquaticus) was used. HotstarTaq polymerases also have the advantage that they only 
activated after an initiation at 95 °C.  The PCR was carried out for 25-30 cycles.  The 
denaturation of DNA takes place at temperatures between 94-96 °C for 30 sec. The temperature 
of the attachment for the specific primer (annealing) is determined according to their melting 
temperature, which in turn depends on the GC content. The elongation step was at 72 °C 
allowing for 1000 bp/1 min extension. The 50 µl reaction contains 200 ng DNA, 1 U 
polymerase, 1x Taq buffer, 200 μM dNTPs (New England Biolabs, Frankfurt, Germany) and 
0.5 μM each forward and reverse primers.  
The Phusion Hot Start II High Fidelity DNA polymerase (New England Biolabs, Frankfurt, 
Germany) was used for cloning, mutagenesis and sequencing. A reaction batch of 50 µl contains 
200 ng DNA, 1 U polymerase, 1x Phusion HF buffer, 3% DMSO, 200 μM dNTPs, and 0.5 μM 
each forward and reverse primer used. The DNA was initially in an initial step denatured at 98 
°C for 30 sec, followed by 25 cycles in which a 10 sec in denaturation step at 98 °C, annealing 
for  30 sec and the elongation of the DNA at 72 °C  with  1000 bp/30 sec .  
2.2.1.2 Gel electrophoresis 
DNA molecules can be sized by agarose gel electrophoresis and be separated from each other. 
The products of the PCR are used in this procedure were applied to a 1% agarose gel, in an 
electric field (electrical chamber with TAE buffer as running buffer) and according to their size 




separated. Because DNA molecules are negatively charged, they migrate toward the positive 
electrode, the anode. Their running speed depends on their size, which means smaller molecules 
will reach the anode faster than larger ones. The separation of the DNA fragments was carried 
out at a constant voltage of 100 V for about 30 min in room temperature (RT). To interpret the 
results, a size standard (e.g. 1kb ladder) was included in each gel electrophoresis. 
To prepare the agarose gel, appropriate amounts of powdered agarose in TAE buffer was boiled,  
after a short cooling phase, ethidium bromide was added (to a final concentration of 
approximately 0.2-0.5 μg/ml) and poured into the mold. Ethidium bromide intercalates into the 
DNA fragments and makes them visible under UV light. The PCR products were mixed with 
loading buffer before application. This stabilizes the pH of the sample, facilitates their handling 
by a color additive and allows the sinking of the sample into the loading pocket of the gels. 
2.2.1.3 DNA isolation and purification 
Contamination of PCR reactions with primer, nucleotides, polymerase or salts were purified 
using the GeneMATRIX Basic DNA Purification kit according to manufacturer’s instructions. 
2.2.1.4 DNA digestion 
Restriction enzyme digestion was carried out for screening of plasmids and recombinant BACs 
as well as for DNA cloning using multiple restriction endonucleases. DNAs were digested 
according to the manufacturer’s recommendations. 
2.2.1.5 DNA de-phosphorylation 
Antarctic phosphatase (AP) was used to prevent self-ligation by removing of 5` phosphate 
groups. Briefly, purified digested plasmid DNA with a single restriction enzyme was incubated 
with AP in the recommended buffer for 1 hour at 37 °C. The AP was inactivated by heating at 
65 oC for 15 min. 
2.2.1.6 DNA gel extraction 
Purification of DNA fragments from agarose gels was carried out by identifying the band of 
interest from the gel using long wavelength UV light. The band of interest was then carefully 
cut from the agarose gel with a surgical scalpel and DNA was purified using the GeneMATRIX 
Basic DNA Purification kit according to manufacturer’s instructions. 




2.2.1.7 DNA ligation 
DNA ligation was carried out by T4 DNA ligase according to manufacturer’s instruction. 
Ligation reaction contains a molar ratio of 3:1 (insert to vector) that was calculated by NEBio 
calculator (http://nebiocalculator.neb.com). A 1-5 µl of the ligation reaction was used to 
transform E. coli competent cells (see Section 2.1.1.3). 
2.2.1.8 Determination of DNA concentration by spectrophotometry 
Concentration and purity of PCR products, plasmids and BACs DNA samples was determined 
using Nanodrop ND1000 low volume spectrophotometer measuring 220 nm to 750 nm 
wavelength with software version 3.7.1 (PeqLab, Erlangen). The 260/280 absorbance ratio was 
used to indicate the contaminants of the DNA samples. 
2.2.1.9 Colony PCR 
A single bacterial colony was used directly as template for PCR to detect correct clones after 
ligation reaction. Single colony was transferred to a new agar plate with appropriate antibiotic 
by a pipette tip and the remains of the cells in the tip were mixed into the PCR reaction using 
Taq DNA polymerase as described previously (see Section 2.2.1.1).  
2.2.1.10 RNA isolation and reverse transcriptase PCR (RT-PCR) 
RNA was extracted from cells using RNeasy Plus Mini kit according to the manufacturer’s 
instruction. Samples were treated with DNase I kit and cDNA was generated using SuperScript 
III Reverse Transcriptase kit following manufacturer’s instruction. RT-PCR was performed on 
cDNA with specific primers using Taq polymerase as previously described (see Section 
2.2.1.1).  
2.2.2 Microbiological Methods 
2.2.2.1 Bacterial culture 
Laboratory strains of E. coli were grown on LB medium or platted on LB agar plates (see 
Section 2.1.6.1). The liquid LB medium and LB agar were sterilized by autoclaving.  For 
positive selection, LB agar was heated by microwave and cooled down to 60 oC and then the 




appropriate antibiotics were added and mixed with LB agar and finally platted in 10 cm petri 
dishes.  
2.2.2.2 Preparation of bacterial stocks for long term storage 
Selected bacterial clones with correctly sequenced BACs or plasmids were stored in glycerol at 
-80 °C for further usage. 
To prepare glycerol stock, a single bacterial colony were inoculated in 3-4 ml LB medium with 
the positively selecting antibiotics for overnight culture at 32 oC or 37 oC with shaking at 220 
rpm in bacterial incubator shaker. The next day, 600 µl of the culture was mixed with 200 µl of 
sterile 60% glycerol in a 1.5 ml eppendorf and stored in -80 oC. 
2.2.2.3 Transformation of chemically competent E. coli 
Chemically competent NEB 10-beta E. coli was used for transformation of plasmids and 
ligation products. NEB 10-beta competent E. coli is a derivative of the popular DH10B strain.  
Transformation steps were carried out according to manufacturer’s protocol. Briefly, tubes of 
NEB 10-beta Competent E. coli cells were left on ice until the last ice crystals disappear. A 1-
5 µl containing 1 pg-100 ng of plasmid or ligation product DNA was added to the cell mixture 
with gently flicking. The cell mixture was then kept for 30 min on ice. The mixture was then 
given a heat shock at 42 oC for 30 sec and then kept on ice for 5 min. A 950 µl of pre-warmed 
supplied growth medium was added to the mixture and then kept for 60 min at 37 oC with 
shaking at 220 rpm in the bacterial incubator shaker. The mixed bacterial cells were then seeded 
down by centrifugation for 5 min at 5000 rpm and resuspended in 100 µl of media and then 
plated on the selective LB agar plated for 18-24 hours. 
2.2.2.4 DNA isolation from bacteria (Miniprep, Midiprep, and BAC Maxi-prep) 
For small-scale plasmid DNA isolation from bacteria (Miniprep), GeneMATRIX Basic DNA 
Purification kit was used according to manufacturer’s instructions. 
Plasmid Midiprep and BAC Maxiprep were carried out using NucleoBond® Xtra Midi and 
NucleoBond® Xtra BAC kits, respectively, following the manufacturer’s instructions. 
 




2.2.2.5 Synthesis of consensus fused HPV16 E6/E7 
The fused form of the modified HPV16 consensus E6/E7 DNA sequence (ConE6E7, GenBank 
accession number: FJ229356) was synthesized and sequenced by Integrated DNA Technologies 
(IDT, Leuven, Belgium). The synthesized ConE6E7 was digested with Kpn-I, cloned into the 
expression vector pcDNA 3.1(+) under the control of the IE promoter of cytomegalovirus and 
the sequence of the insert was confirmed by PCR and sequencing, this construct was named as 
pcDNAE6/E7Kpn-I . 
ConE6E7 was amplified and cloned into pJET 1.2 vector at EcoRV restriction site using primers 
conE6E7EcoRVF and conE6E7EcoRVR, this plasmid was named as pJetConE6E7. Then, the 
kanamycin cassette was amplified from pEPkan-S plasmid using primers conE6E7BamHF and 
conE6E7BamHR and the amplified fragment was inserted into BamHI restriction site, this 
plasmid was named as pJetConE6E7kan. A shuttle vector was constructed using pEF6/V5-His 
A plasmid, in which ConE6E7 with kanamycin cassette were inserted at EcoRI restriction site 
using primers pEF_E6/E7F and pEF_E6/E7R, the plasmid was named as pEF6E6/E7EcoRI.  
2.2.2.6 Two-step Red-mediated recombination (En passant mutagenesis) [242, 248] 
All HCMV recombinant viruses generated in this study were genetically modified using the 
most efficient mutagenesis that allows introduction of the desired mutations including 
insertions, deletions, point mutations or tags into herpesvirus DNA called Two-step Red-
mediated mutagenesis technique system (En passant mutagenesis). This system was originated 
from phage λ (lambda phage) and composed of three major protein which are Exo, Beta and 
Gam proteins components [242, 248]. These proteins can be activated at 42 oC. Linear double 
stranded DNA inserted to E. coli can be degraded by the action of E. coli RecB/C/D helicase–
nuclease complex; Gam protein of the Red-recombination system inhibits this complex and 
maintains the inserted linear DNA. On the other hand, Beta protein protects the 5`-3` 
exonuclease action of homotrimer Exo protein, it also anneals the 3’ single strand end produced 
from the linear DNA with complementary homologous sequences in the desired target. 
Generally, complementary homologous sequence of 30-50 bp is sufficient to allow integration 
into replicating DNA in Red recombination system. 
All mutagenesis steps were carried out in GS1783 E. coli strain harbors HCMV BACs with 
temperature-inducible Red-recombination system, as well as arabinose induced the I-SceI 
homing endonuclease, and chloramphenicol resistance marker. Shuttle plasmids were initially 




designed which encode the sequence to be inserted into the BAC sequence. These shuttle 
plasmids were used as PCR template, from which the fragments to be inserted into HCMV 
BAC are amplified with primers with 40 bp of homology to the desired target sequence in the 
BAC. The PCR products were digested with DpnI enzyme to get rid of the original plasmids 
and then purified by PCR cleanup or agarose extraction (see Section 2.2.1.3 and 2.2.1.6). A 150 
ng of the clean linear PCR were electroporated into electrocompetent GS1783 E. coli harboring 
the HCMV BAC. 
To generate electrocompetent GS1783 E. coli, GS1783 was grown overnight at 32 oC in 3 ml 
LB-cam medium. In the next day, 50 ml were inoculated with the 500 µl of overnight culture 
and incubated at 32 oC under vigorous shaking (220 rpm). The logarithmic growth phase (at 
OD600) was measured after 2-4 hours till it reaches OD600 0.5 - 0.7, then the culture was 
transferred to water bath shaker at 42 oC for 15 min at 200 rpm to activate the Red-
recombination system. The culture then was cooled down on water-ice bath for 15 min and kept 
on a shaker at RT. The culture was pelleted by centrifugation (5000 rpm, 5 min at 4 oC), 
followed by three times washed with 25 ml of an ice-cold sterile millipore water and finally 
resuspended in 100 µl sterile millipore water. A 40-50µl of the bacterial suspension was used 
for the electroporation step. Electroporation was carried out in 1 mm pre-chilled cuvette at 1.6 
kV, for time constant (Ʈ) 5 msec using the Multiporator device. 
Samples were resuspended in 1000 µl of pre-warmed LB medium (without antibiotics) and 
incubated for 1-2 hours at 32 oC with shaking at 220 rpm. The bacteria were afterwards pelleted 
by centrifugation (5000 rpm, 5 min, RT) and resuspended in 100 µl of the LB medium and 
plated on selective LB-cam-kan agar plates for 24-48 hours. 
 
 

















































Figure 8. Schematic representation of the two step Red-mediated recombination procedure. Two-
step Red-recombination was used for insertion of fragments into HCMV-BAC. First, the kanamycin 
cassette as positive selection marker (psm) obtained by a PCR from pEPkan-S contains I-SecI site (S) 
with homologous sites (red box) is cloned into the single restriction site (*) of the shuttle plasmids. After 
PCR amplification with primers that have homologous flanks to desired location in BAC (green and 
blue lines), the first recombination step is performed in which the PCR product is integrated into the 
genome. The following process, resolution, is the excision of the positive selection marker (kan). 
Modified from Tischer et al., 2006 [242]. 
 




For scarless excision of the positive selection marker (kan) in the second Red-recombination 
step (resolution), the correctly modified BACs in GS1783 from overnight culture were grown 
for 2 hours in 2 ml of LB-cam media at 32 oC with shaking at 220 rpm. To induce the expression 
of I-SceI, 2 ml of fresh LB-cam containing 1% L-(+)- arabinose was added to the culture and 
incubated for 2 hours at 32 oC with shaking at 220 rpm, then cultures were then transferred to a 
42°C water bath shaker (150 rpm) for 30 min to activate the Red-recombination system for the 
second recombination step between duplicated sequences (Figure 8, shown in red). The 
bacterial cultures afterwards were grown for another one hour at 32 oC in bacterial incubator 
shaker with shaking at 220 rpm. Finally,100 µl of 1x10-3 dilution was spread on LB-cam-1% 
L-(+)- arabinose agar plates, incubated for 48 hours at 32 oC. The final clones were tested for 
the absence of kanamycin resistance on replica plates with LB-cam-kan and LB-cam. Selected 
clones were investigated by restriction fragment length polymorphism (RFLP) screening 
analysis using multiple restriction enzymes and were compared to a predicted banding pattern. 
Moreover, these mutations were confirmed by PCR and sequencing as well. 
2.2.3 Cell culture methods 
2.2.3.1 Cell thawing and culture 
The cells were thawed in their cryopreservation tubes and placed under sterile transfer 
conditions to a 15 ml falcon tube containing 10 ml of cell-specific medium. Afterwards, the 
cells were centrifuged at 300 x g for 5min, RT. The supernatant is discarded and the cell pellet 
in a sufficient amount of fresh medium resuspended. The cells are transferred to a multi-well 
plate or cell culture flasks and filled with medium according to their quantity. The cultivation 
takes place in the cell culture incubator at 37 oC and 5% CO2. 
2.2.3.2 Cell feeding and medium change 
Depending on their requirements, the cultured cells were regularly supplied with fresh medium. 
Sometimes, adding a good amount of fresh medium to it is enough. With a strong consumption 
of the presented nutrients, it is recommended to partial replace the old medium by 50% with a 
fresh one. The complete decline of the conditioned medium may cause shock for cells 
depending on the cell type and this is not recommended. 
 




2.2.3.3 Cell passaging 
Suspension cells can be divided as desired or lower concentrated by a removing certain amount 
of cells from a culture vessel, transferred to a new one and filled with fresh medium. 
For adherent cells, the old medium is removed, and the cell rinsed with 1x PBS with the 
recommended amount without damaging them. Cells were then detached from the bottom of 
the cell culture vessels with a small amount of trypsin according to the size of cell culture plate 
or flask. 
After a short reaction time (2-5 min) in the cell culture incubator, cells were treated by the 
addition of fresh medium and the cells were mixed with medium using sterile cell culture 
pipettes. The enzymatic reaction of trypsin is stopped, and the complete degradation of the cells 
prevented by the addition of the fresh medium. The cells can then be counted (see Section 
2.2.3.6), distributed to new culture vessels, or in portions to be frozen. 
2.2.3.4 Cryopreservation of cells 
The suspension cells to be frozen had to be suspended in PBS first. For adherent cells, cells had 
to be trypsinized first and washed once with the recommended medium and afterwards 
resuspended in PBS in 15 ml sterile falcon tube. 
The cells were then counted (see Section 2.2.3.6), and afterwards centrifuged for 5 min at 300 
x g, RT. The PBS was removed, and cells were resuspended in a desired amount of FCS.  
Cells were then aliquoted in the 2ml cryopreservation tubes. An equal volume of FCS 
containing 20% sterile DMSO was added to each tube and the tubes were mixed gently by 
inverting for 5 times. The final cell number in each tube should not exceed 1x107cells/ml. The 
cryopreservation vials were then transferred into a Mr. Frosty container (at room temperature) 
and put into a -80°C freezer. The Mr. Frosty container ensures that the temperature decreases 
steadily by 1 oC/min. After approximately 24 hours, the cryopreservation vials were transferred 
from the Mr. Frosty container into liquid nitrogen for long term storage. 
 
 




2.2.3.5 Isolation of peripheral blood mononuclear cells (PBMCs) 
Buffy coat preparations were purchased from German Red Cross (Dresden, Germany). Blood 
samples were taken with the approval of the ethics committee of the 
Charité−Universitätsmedizin Berlin. Written informed consent was obtained from all donors. 
The delivery to our laboratory took place within 24 hours; storage and transport were carried 
out at room or vehicle temperature. The blood was transferred from the preserved blood bag to 
sterile falcon tubes and diluted 1: 3 with PBS. Subsequently, the diluted blood was pipetted in 
a ratio of 3:2 onto a layer of Ficoll-Paque (Roti®-Sep 1077 human); a 50 ml sterile falcon tube 
thus contained 30 ml of blood to 20 ml of Ficoll-Paque. 
In order to avoid a mixing of the layers, particularly slow and careful overlapping was 
necessary. This was followed by centrifugation at 400 x g in a swinging-bucket rotor for 30 min 
at RT without brake. After centrifugation, the supernatant portion of plasma was carefully 
pipetted off about 1 cm above the ring of mononuclear cells without mixing the layers. The 
cells were then carefully removed with a sterile Pasteur pipette and transferred to a 50 ml sterile 
falcon tube. Then the falcon tube was afterwards filled up to a total volume of 45 ml with PBS. 
The cells were afterwards centrifuged at 300 x g for 10 min at room temperature. The 
supernatant was pipetted off and the cell pellet resuspended in the residual volume. For 
erythrocyte lysis, 3 ml of RBC lysis buffer was added and incubated for 5 min on ice. 
Afterwards, the reaction was stopped by adding PBS to a total volume of 45 ml. It was again 
centrifuged at 300 x g for 10 min. The supernatant was removed, and the cells washed twice 
with PBS. Finally, the cells pellet was resuspended in 10 ml PBS. The cells were counted after 
appropriate dilution (see Section 2.2.3.6), and then cultured in RPMI 1640 medium. 
2.2.3.6 Cell counting 
Cells to be counted should be in suspension. For vital staining trypan blue was used; trypan 
blue penetrates defective cell membranes and stains corresponding cells dark blue. Living cells 
and cells with an intact cell membrane remain bright. The staining was carried out in a ratio of 
1:1, for example 100 μl trypan blue (0.4% initial concentration) to 100 μl cell suspension. 
Subsequently, the cell suspension was applied to a Neubauer counting chamber. 
At high cell concentrations, a dilution was first required. At high cell numbers (> 200 cells per 
corner square), the count is no longer possible due to the high cell density. The living unstained 




cells in 4 large corner squares were counted under the microscope and an average value was 
formed division by 4. Cells touching the left or top lines were counted, but cells at the bottom 
or right margins were not counted. The microscopy work was performed at the microscope 
workstation outside the sterile bench. To determine the number of cells per μl, the average of 
the counted cells was multiplied by the chamber factor and the dilution factor. 
The chamber factor results from the reciprocal of the volume of a corner square (0.1 μl) and is 
thus 10. In order to determine the total cell number of the cell suspension, the number of cells 
per μl was multiplied by the total volume of the suspension. 
2.2.3.7 Surface expression of HLA-A2 molecules 
Cell surface expression of HLA-A2 molecules was measured by FACS as previously described 
using PE-conjugated anti- HLA-A2 antibody clone BB7.2 [249]. 
2.2.4 Virological methods 
2.2.4.1 Stable mammalian cells transfection by electroporation 
U251 cells were used in this study for stable plasmid transfection by electroporation. Cells were 
trypsinized form cell culture plate and washed once with PBS and counted (see Section 2.2.3.6). 
About 2X106 cells were transferred to another 15 ml sterile falcon tube and centrifuged for 5 
min at 300 x g, RT and resuspended in 150 µl in hypo-osmolar buffer for eukaryotic cells 
electroporation in 1.5 µl eppendorf. About 3 µg of plasmid (pcDNAE6/E7Kpn-I) was diluted 
in 50 µl iso-osmolar buffer and then added to the cells and mixed gently by tipping and left for 
30 min incubation at RT. The cells mixture was then transferred to 2 mm cuvette and was pulsed 
at 240 V for time constant (Ʈ) 40 μsec using the Multiporator device. After the pulse the cells 
were kept standing in the cuvette for 5 to 10 minutes at RT and then transferred to the culture 
medium. 
After 48 hours, the culture medium was changed, and the cells were fed by fresh medium 
containing the selection antibiotic (G418) at final concentration of 1 mg/ml. The medium was 
changed every 3 days with keeping the selective antibiotic at the same concentration. 
After two weeks of positive selection, different cell clones were isolated using the cloning rings 
as described previously [250]. Different clones were allowed to expand in cell culture in 
separate cell culture wells and plates for further investigations. 




2.2.4.2 HCMV reconstitution from BACs 
All modified HCMV BACs in this study were reconstituted in Fi301 cells using Basic 
NucleofectorTM kit for primary mammalian fibroblasts following the manufacturer’s 
instructions. 
Briefly, about 3 µg of the purified DNA BACs (see Section 2.2.2.4) was used for HCMV 
reconstitution, the cells were given a pulse using program A-024 of the NucleofectorTM 2b 
device. 
On the next day, culture media was changed, and more fibroblasts were added to the transfected 
cells to keep cell confluency 70-90%. The culture was kept for two weeks with medium change 
every 4 days. The typical cytopathic effect (CPE) of HCMV appears in 7-14 days after 
transfection, the infected cells were mixed with fresh non-infected Fi301 in a T-75 cell culture 
flask and kept for another 7-10 days till were fully infected. The infected cells were then 
passaged to infect two T-175 flasks of Fi301 cells. 
2.2.4.3 HCMV stock generation 
To generate high titer of HCMV stocks, Fi301 cells were used in T-175 cell culture flasks with 
70% confluency. The cells were infected at multiplicity of infection (MOI) 0.01-0.02 and the 
infected cells were kept in culture till the cells were fully infected. The supernatant was 
collected, and the cells were scraped by cell culture scrapers and then resuspended in a 
minimum residual volume (about 2 ml) and cell were afterwards transferred to a 15 ml sterile 
falcon tube and kept for -80°C overnight. The cells were then handled for two freezing-thawing 
cycles with a vortex in between and then cell debris were removed by centrifugation at 200 x g 
for 5 min, RT. The cell lysate was collected in another 15ml sterile falcon tube.  
The collected supernatant was handled separately; the supernatant was ultra-centrifuged for 1 
hour at 20,000 rpm, 4 oC. The virus pellets were then combined to the same falcon tube 
containing HCMV from the cell lysate and aliquoted in 1.5 eppendorf tubes and kept in -80 oC. 
2.2.4.4 HCMV infection of cells 
Cells were infected with HCMV using different volumes from the virus stock based on the 
tissue culture infection dose 50 per ml (TCID50/ml) of a virus stock. TheTCID50/ml describes 




the amount of a virus dilution needed to infect 50 % of all cells. To determine the volume of 
virus stock needed to infect cells at a given MOI the following equation was used:  
𝑁𝑢𝑚𝑏𝑒𝑟𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 ∗ 𝑀𝑂𝐼
𝑇𝐶𝐼𝐷50/𝑚𝑙
= volume of virus stock in ml  
The required volume from virus stock was used to infect cells by adding this volume to the 
attached cells. The culture plates were afterwards rocked gently to ensure even cell infection 
and then kept in cell culture incubator. After 30 min the plates were rocked gently once again 
and returned back to the incubator. 
2.2.4.5 HCMV titration and growth kinetics 
Virus titers of virus stocks and multi-step growth kinetics were quantified by TCID50 assay on 
Fi301 cells. The TCID50 values were calculated using the method of Reed and Muench [251]. 
2.2.4.6 HLA ligandome analysis 
HLA-A2 Fi301 were cells were left uninfected or infected with HCMV (MOI 1). The cells were 
harvested after 48 hours, washed twice with cold PBS, and stored frozen at −80 oC. The cells 
were sent to Prof. Stefan Stevanovic (Department of Immunology, Institute for Cell Biology, 
University of Tübingen, Tübingen) where the cells were subjected to subsequent isolation of 
HLA peptides using standard immunoaffinity purification and mass spectroscopy, as described 
previously [252, 253]. 
Peptides-source proteins were annotated using Uniprot and NetMHCpan 4.0 [254] and were 
classified according to subcellular locations and biological functions using human protein 
reference database [255]. 
2.2.5 HPV oncoprotein assay 
2.2.5.1 HPV16-encoded E7 protein assay 
Expression of the oncoprotein E7 was detected by recomWell HPV16/18/45 ELISA kit. All 
steps were done at RT. Cells were trypsinized, centrifuged at 600 x g for 15 min, supernatant 
discarded, and the pellet resuspended in 250 µl of lysis solution A by vortexing for 3 sec. After 
an incubation for 30 minutes 250 µl of lysis solution B was added and vortexed for 3 sec. A 
100 µl aliquot of the lysate was applied to one well of the ELISA plate and incubated for one 




hour. The plate was washed three times with 300 µl washing buffer and tapping it firmly. The 
detection antibody (100 µl/well) was added and incubated for one hour. The plate was washed 
three times. streptavidin conjugate (100 µl/well) was added und incubated for one hour. The 
plate was washed six times and the substrate solution (100 µl/well) was added and incubated 
30 min in the dark.  Stop solution (100 µl/well) was added and the absorbance was read at 450 
nm in the Multiskan FC microplate photometer. 
2.2.5.2 HPV16-encoded E6 protein assay 
OncoE6 Cervical Test™ kit (Arbor Vita, USA) was used to detect expression of the oncoprotein 
HPV16 E6. All steps were done at RT. The trypsinized 1x106 cells were centrifuged at 10,000 
x g for 5 min and supernatant was discarded. A volume of 930 µl rinse solution was added to 
the tube containing the cell pellet, the tube was shaken vigorously and centrifuged at 10,000 x 
g for five minutes. After discarding the supernatant, a volume of 186 µl of lysis solution was 
added to the cell pellet. The tube was shaken followed by rotating at 8 rpm for 15 min. After a 
centrifugation at 10,000 x g for 15 sec, 17.5 µl conditioning solution was added to the tube. The 
tube was shaken and rotated at 8 rpm for 15 min. After centrifugation at 10,000 x g for 15 sec, 
a 200 µl aliquot of the lysate was filled into the antibody-coated detector vial and slowly tilted 
for antibody resolution. The test unit was inserted into the lysate and incubated for 55 min, then 
transferred into a vial containing 200 µl washing solution and incubated for 12 min, and then 
transferred into a vial containing 650 µl development solution and incubated for 15 min. The 
test unit was immediately placed onto a reading guide for result interpretation. Appearance of 
a test line indicated positive detection of oncoprotein E6. Different expression levels could be 
distinguished by the color intensities of the test lines.  
2.2.6 Functional T cell assay 
In collaboration with Prof. Gerald Willimsky (Institute of Immunology, Charite 
Universitätsmedizin Berlin, Berlin), PBMC isolated from healthy donors (see Section 2.2.3.5) 
and Jurkat cells were transduced by retrovirus encoding specific TCRs specific for HLA-A2-
restricted HPV16 E6 or HCMV pp65 peptides. 
 
 




2.2.6.1 Generation of TCR expression vectors 
For HPV E629-36-specific TCR [256], transgene cassettes were codon-optimized for human 
expression and synthesized by GeneArt (Life Technologies, Darmstadt, Germany). TCR-α/β 
chains with human TCR constant regions replaced by their murine counterparts were linked via 
2A “self-cleaving” peptide sequence from Porcine teschovirus-1 (P2A) and cloned in the 
configuration TCRβ-P2A-TCRα into pMP71-PRE using NotI and EcoRI restriction sites as 
described before [257],  the plasmid named as pMP71-PRE-E6. The CMV-specific TCR (NLV-
3) was used in its original configuration as described previously (MP71TCRα and MP71TCRβ) 
[247]. 
2.2.6.2 TCR gene transfer 
TCR gene transfer was carried out as described previously [246].  In brief, HEK-293T cells 
stably expressing GALV-env and MLV-gag/pol were grown to approximately 80% confluence 
and transfected with 3 µg of pMP71-TCR vectors in the presence of 10 µg Lipofectamine2000 
(Life Technologies, Germany). A 3 ml of retrovirus containing supernatant were harvested 48 
hours and 72 hours after transfection.1 x 106 from Jurkat cells or frozen human PBMCs, isolated 
as described previously (see Section 2.2.3.5), were stimulated with 5 µg/ml anti-CD3 (OKT3) 
and 1 µg/ml anti-CD28 (CD28.2) coated plates in the presence of 300 U/ml recombinant human 
interleukin 2 (hIL-2) .Transductions at 48 hours and 72 hours after stimulation were performed 
by addition of retrovirus containing supernatant and 4 µg/ml protamine sulfate (Sigma-Aldrich, 
Steinheim, Germany) followed by spinoculation for 90 min at 800 x g and 32 oC (1st 
transduction). For 2nd transduction retrovirus was preloaded onto retronectin- coated plates 
followed by spinoculation for 30 min at 800 x g and 32 oC. Transduced T cells were kept in the 
presence of 300 U/ml hIL-2 for a total of 2 weeks. At least 2 days prior experiments, PBMCs 
to be transduced were cultured in the presence of 30 U/ml hIL-2.  
2.2.6.3 Functional assays using transduced PBMCs 
Interferon-γ (IFN-γ) production was measured by ELISA using the standard protocol after 16 
hours co-culture of 1x105 TCR-transduced T cells with 1x105 target cells (HCMV-infected or 
peptide-loaded cells). Stimulation with phorbol myristate acetate and ionomycin (P+I) was used 
as a positive control.  
 




2.2.6.4 Functional assays using transduced Jurkat cells 
For detection of nuclear factor of activated T-cells (NFAT) activation, a previously described 
cellular platform for analysis of TCRs was used [258, 259]. In the human lymphoma T cell line 
Jurkat 76 (J76),  the response elements of transcription factor NFAT drive the expression of 
EGFP [258]. The J76 cell line is a subline of cell line Jurkat E6.1 (JE6.1), which lacks 
expression of the TCR alpha and beta chains [260]. The J76 cell line was transduced with a 
retroviral vector encoding HLA-A2‐restricted HPV E629-36-specific TCR [256]. Moreover, J76 
cells were co-transduced  to express an HLA-A2‐restricted HCMV pp65-specific TCR 
(NLVPMVATV; aa 495-503) and CD8 [259]. 
For measuring of nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) 
activation a single T cell reporter cell line was used, in which the responsive element for NF-
κB controls EGFP expression [261]. This single reporter cell line was transduced with retroviral 
vector encoding HLA-A2‐restricted HPV E629-36-specific TCR [256] or with retroviral vector 
encoding the CMV-specific TCR (NLV3), which recognizes an HLA-A2‐restricted epitope 
derived from pp65 (NLVPMVATV; aa 495-503) [247]. 
2.2.6.5 Acid wash of MHC-I associated peptides 
U251 stably transfected cells with pcDNAE6/E7Kpn-I (pcDNAE6/E7Kpn-I U251 cells) as 
previously described in (see Section 2.2.4.1) were left uninfected or infected with 
RVTB40ΔUS11 for 3–24 hours at different MOIs. RVTB40ΔUS11 lacks all known HCMV-
encoded immune evasion genes (US2, US3, US6, and US11) that target MHC-I presentation 
and does not downregulate MHC-I molecules. On uninfected and infected pcDNAE6/E7Kpn-I 
U251 cells, the existing peptide-MHC-I complexes on U251 cells were removed by acid wash 
as previously described [262]. Briefly, 1 × 106 cells were harvested, washed with PBS and 
subsequently washed with ice-cold citric acid buffer (pH 3) for 2–3 min. Afterwards, stripped 
pcDNAE6/E7Kpn-I U251 cells were pelleted, washed twice with EMEM medium, resuspended 
in RPMI 1640 medium and subsequently co-cultured for 18 hours with the HPV E629−36-
specific reporter cell line, in which the responsive element for NF-κB controls EGFP expression 
[263]. Finally, EGFP expression of reporter cells was determined by FACS analysis. In parallel, 
the maximal peptide stimulation was always determined by pulsing a cell aliquot with the E6 






3.1 Deletion of MHC-I downregulating genes from HCMV 
3.1.1 Deletion of MHC-I downregulating genes from the genome of HCMV strain Merlin 
In order to optimize HCMV as a vaccine vector, MHC-I downregulating genes were deleted to 
potentiate CTL-mediated immune response. We initially used the Merlin strain as this is the 
closest to wild-type HCMV [245]. 
Although different BACs of HCMV strain Merlin have been constructed, only one of these 
BACs was used in this study (RCMV1161). This BAC had been repaired for RL13 and UL128 
regions which were previously lost due to virus adaption during passaging in fibroblasts. It also 
encodes for EGFP cassette under the control of HCMV IE2 [245]. 
MHC-I downregulating genes (US2, US3, US6 and US11) were deleted sequentially using 
specific primers (see Section 2.1.11). The En passant mutagenesis steps were carried out as 
previously described (see Section 2.2.2.6).  
Each mutagenesis process was carried out in two steps. Firstly, the gene to be deleted was 
replaced by the kanamycin cassette. Secondly, excision (resolution) of the kanamycin cassette 
was performed (Merlin1161∆US2-BAC, Merlin1161∆US2∆3-BAC, Merlin1161∆US2∆3∆6-
BAC and Merlin1161∆US2∆3∆6∆11-BAC) as shown in Figure 9. 





























Figure 9. RFLP patterns for RCMV1161 HCMV mutants with MHC-I downregulating genes 
deletion. (A) Patterns obtained by restriction enzyme EcoRI. The DNA was run through an 0.8% agarose 
gels overnight at 65 V. (B) Vector NTI 9.1 prediction of RFLP patterns are shown with size markers 
from 7 to 20 kb. 
 
All mutants were sequenced for the modified regions confirming the deletion of these genes 
(data not shown). However, none of these mutants could be successfully reconstituted by 
nucleofection (see Section 2.2.4.2). Although transfected cells were kept in culture over three 
weeks, only single green cells were detected confirming that the mutated (unrepaired) forms of 












Figure 10. Reconstitution of Merlin HCMV (RCMV1161). Fi301 cells were transfected by 
RCMV1161 using nucleofection. The image shows EGFP-Fi301 cells using fluorescent microscopy. 







3.1.2 Deletion of MHC-I downregulating genes from HCMV (TB40-BAC4) 
Another HCMV strain was also included in our study to develop vaccine vectors. TB40/E 
(TB40-BAC4) is promising as a vector because it is adapted to cell culture and hence is easier 
than HCMV strain Merlin (RCMV1161) to reconstitute and expand. Moreover, it can infect 
endothelial cells and DCs while the laboratory strain AD169 cannot, making it a good candidate 
to drive a CTL-mediated  inflationary response in vivo [264].  
The mini-F sequence (the BAC backbone) has replaced the region for US2-US6 in TB40-
BAC4. For this reason, US11 was the only remaining MHC-I modulating gene that had to be 
deleted in order to fully optimize TB40-BAC4 by En passant mutagenesis (see Section 2.2.2.6). 
This optimized vector was named as RVTB40ΔUS11 as shown in Figure 11. 
 
Figure 11. Deletion of US11 gene from HCMV TB40-BAC4. (A) Schematic diagram of TB40-BAC4 
showing the deletion US11 (RVTB40ΔUS11-BAC). (B) PCR from up and down-stream of US11 
(primers SeqUS11F and R) confirming the insertion and the excision of the kanamycin cassette from 
TB40-BAC4 using 1 kb DNA ladder GeneSTA (M). The fragment amplified from RVTB40ΔUS11-
BAC was sequenced using the same primers and the results confirmed the deletion of US11 gene (data 
not shown). 
RVTB40ΔUS11-BAC was successfully reconstituted as previously described (see Section 
2.2.4.2) and the virus growth kinetics were analyzed by TCID50 determination as previously 
described (see Section 2.2.4.4). The results showed that RVTB40ΔUS11 can grow in fibroblasts 





In order to investigate the effect of all MHC-I downregulating genes (US2, US3, US6 and 
US11) on the expression and presentation of MHC-I (HLA-A2) molecules, Fi301 infected with 
TB40/E WT or RVTB40ΔUS11 (MOI 0.5) were stained for HLA-A2 molecules as described  
(see Section 2.2.3.6) and shown in Figure 12.  
Figure 12.  Characteristics of RVTB40ΔUS11 mutant. (A) Fi301 cells were infected with WT 
TB40/E or RVTB40ΔUS11(ΔUS11) at MOI of 0.5. After 2 days cells were stained with HLA-A2 
specific antibody or isotype control and analysed by flow cytometry. (B) Multi-step growth kinetics of 
TB40/E WT (WT) or RVTB40ΔUS11(ΔUS11). Fi301 cell were infected with HCMV at MOI 0.01 and 
the supernatant was collected at different days post infection (p.i.) and was titrated for HCMV as 
described previously (see Section 2.2.4.5).  Results are derived from three independent experiments; 
error bars represent the mean ± SEM. 
3.2 Infection of GBM cell lines by HCMV 
In order to investigate the HLA-A2 GBM selected in this study for their susceptibility to 
HCMV, GBM cell lines (LN18, U343 or U251 cells) were infected by RV-TB40-BACKL7-SE-
EGFP HCMV (MOI 0.3). At different time points post infection, the percentage of EGFP-
expressing GBM cells was measured by FACS and they were all permissive to HCMV at 









Figure 13. Permissiveness of GBM to RV-TB40-BACKL7-SE-EGFP HCMV. GBM cells were analyzed by 
FACS for EGFP expression at different time points p.i. Results are derived from three technical replicates; error 





The supernatant of the infected GBM cell line was also analyzed for the presence of cell-free 
HCMV. The supernatant was collected at the same time points and used to infect Fi301 cells 
which were further analyzed by FACS after two days for EGFP expression. The results showed 




Figure 14. RV-TB40-BACKL7-SE-EGFP HCMV detection in the supernatant of the infected GBM cells. The 
results show the percentage of the Fi301 cells infected by the supernatants collected from RV-TB40-BACKL7-SE-
EGFP-infected GBM cell lines. Results are derived from three technical replicates; error bars represent the mean 
± SEM.  
3.3 Construction of HCMV-based vaccines 
The modified HCMV lacking all MHC-I downregulating genes (RVTB40ΔUS11-BAC) was 
used to construct all HCMV-based vaccines. 
3.3.1 Optimized HCMV-based vaccines expressing fused HPV16 E6/E7 protein 
3.3.1.1 Construction of HCMV-based vaccines with E6/E7 expression under control of 
endogenous or exogenous promoter 
In order to investigate the capacity of recombinant HCMV-based vaccines to stimulate T cells, 
four different vaccines were constructed by En passant mutagenesis (see Section 2.2.2.6). All 
these viruses were constructed using a shuttle plasmid (pEF6E6/E7EcoRI), which encodes the 
E6/E7 under the control of EF-1 promoter. The kanamycin cassette was also cloned into this 
vector inside the E6/E7 sequence (see Section 2.2.1.4). 
Three viruses were constructed with E6/E7 expression under the control of endogenous HCMV 





promoter with minimum change of the viral sequence. In this virus, the E6/E7 sequence 
replaced the sequence of US11. The E6/E7 sequence with kanamycin cassette was amplified 
(using US11ConE6E7F and R primers) and the amplified PCR product was used to generate 
recombinant HCMV; this BAC was named as RVTB40E6/E7intoUS11-BAC (Figure 15). 
We also sought to investigate the expression of the E6/E7 protein combined with interruption 
of other immune evasion genes. The amplified E6/E7 sequence (using IL-10FusedE6/E7F and 
R primers) was used to insert the E6/E7 sequence into UL111A, which is expressed in both 
lytic and latent infection. This BAC was named RVTB40ΔUS11_E6/E7intoUL111A-BAC 
(Figure 15). Another vaccine candidate was also constructed by replacing UL83 (using 
UL83FusedE6/E7F and R primers); this BAC was named RVTB40ΔUS11_E6/E7intoUL83-
BAC (Figure 15). 
The expression of E6 and E7 under exogenous promoter control was investigated by the 
amplification of the E6/E7 sequence together with EF-1 promoter and were subsequentially 
inserted into RVTB40ΔUS11-BAC downstream of the mini-F sequence. To construct this 
virus, the primers EF-1E6/E7F and R were used, and the generated BAC was named 
RVTB40ΔUS11_EF-1E6/E7-BAC (Figure 15). 
To confirm the construction of recombinant HCMV-based vaccines, PCR using primers 
flanking the target site was carried out (Figure 16) and the amplified fragments from final 
















Figure 15. Construction of HCMV-based vaccines expressing the full E6/E7 protein. (A) 
RVTB40_E6/E7intoUS11-BAC with E6/E7 was expressed under the control of the endogenous US11 
promoter. (B) UL111A has alternative splicing in lytic (cmvIL-10) and latency associated form (LA-
cmvIL-10). RVTB40∆US11_E6/E7intoUL111A-BAC was constructed by inserting the E6/E7 fusion 
sequence into the second exon. This construction allows the expression of E6/E7 protein in lytic and 
latent HCMV infection (C) RVTB40∆US11_E6/E7intoUL83-BAC. The E6/E7 protein was expressed 
under the control of the UL83 promoter. (D) RVTB40∆US11_EF-1E6/E7-BAC. The E6/E7 protein was 



















Figure 16. Confirmatory PCR for HCMV-based vaccine expressing the E6/E7 protein. PCR was 
carried out using primers flanking the target regions. PCR using primers SeqUS11F and R , SeqUL111F 
and R, SeqUL83F and R, and seqEF-1E6/E7 showing the insertion of the E6/E7 sequence in 
RVTB40_E6/E7intoUS11-BAC (A) RVTB40∆US11_E6/E7intoUL111A-BAC (B), 
RVTB40∆US11_E6/E7intoUL83-BAC (C), and RVTB40∆US11_EF-1E6/E7-BAC (D), respectively. 
The 1 kb DNA ladder GeneSTA was used (M). The amplified DNA fragments from the final mutants 
were sequenced using the same primers (data not shown). 
3.3.1.2 Growth kinetics of HCMV-based vaccines expressing E6/E7 protein 
Multi-step growth kinetics were carried out for all recombinant viruses in Fi301 cells as 
previously described (see Section 2.2.4.5). TCID50 was determined at different time points p.i. 












Figure 17. Growth curve kinetics of E6/E7 expressing vaccines. Fi301 cells were infected at MOI of 
0.01. Supernatant was collected at different time points after infection and titrated on Fi301 cells to 
calculate the TCID50. Results are derived from three independent experiments; error bars represent the 
mean ± SEM. Results were analyzed using Two-way ANOVA and there was no significant difference 
among the growth curves (P value 0.1313). 
3.3.1.3 Expression of E6 and E7 proteins by HCMV-based vaccines 
3.3.1.3.1 Transcription analysis of E6 and E7 genes using RT-PCR 
In order to confirm the transcription of E6 and E7, Fi301 cells were infected with 
RVTB40ΔUS11 or HCMV-based vaccines expressing E6/E7 protein (MOI=1). RNA isolation 
and RT-PCR were carried out as previously described (see Section 2.2.1.10). All recombinant 
viruses showed expression of E6 and E7. There was no expression of cmvIL-10 in 
RVTB40∆US11_E6/E7intoUL111A and UL83 in RVTB40∆US11_E6/E7intoUL83 as these 



































Figure 18. RT-PCR for HCMV-based vaccines expressing E6/E7 protein. 1x106 Fi301 cells were 
infected at MOI 1 and RNA was extracted after 18 hours. (A) PCR was done for E6 and E7 without 
reverse transcriptase (-RT) or after reverse transcriptase (+RT) using primers (E6RT F and R) for E6 
and (ER7T F and R) for E7. (B) PCR was done on +RT samples for UL111A (vIL-10) using primers 
SeqUL111 F and R or UL83 using primers UL83RT F and R. 
3.3.1.3.2 Expression analysis of E6 and E7 proteins 
3.3.1.3.2.1 Detection of HPV16 E6 protein 
For analyzing oncoprotein expression from HCMV mutants and pcDNAE6/E7Kpn-I U251 
cells, OncoE6 Cervical Test™ kit was used to detect expression of oncoprotein E6 as previously 
described (see Section 2.2.5.2). Appearance of a test line indicated positive detection of 
oncoprotein E6.  
All cells infected with recombinant viruses (MOI 1) as well as pcDNAE6/E7Kpn-I U251 cells 
showed high band intensity for E6 protein. Different expression levels could be distinguished 
by the color intensities of the test lines. The band intensity decreases in accordance with the 





Figure 19. OncoE6 Cervical Test for HPV16 E6 detection. (A) E6 was detected in different infected 
Fi301 (MOI 1) or pcDNAE6/E7Kpn-I U251 (750.000 cells) with different signal strengths. The bars 
represent the mean of two independent experiments ± SD. (B) the read out for the test shows the signal 
for same number of CaSki cells as positive control.  (C) Test read-out showing different signal strength 
detected upon with different cells number infected with RVTB40_E6/E7intoUS11 which are 750.000 
cells (lane 1 with signal strength 5), 75.000 cells (lane 2 with signal strength 1), and 7500 cells (lane 3 
without detection of E6). 
3.3.1.3.2.2 Expression analysis of HPV16 E7protein 
In order to analyze the expression of E7 protein in recombinant HCMV or in pcDNAE6/E7Kpn-
I U251cells, recomWell HPV16/18/45 ELISA kit was used as previously described (see Section 
2.2.5.1). All recombinant HCMV-expressing E6/E7 protein showed higher expression of E7 
protein compared to CaSki cells which were considered the positive control, as they have 
integrated HPV16 genome. The results showed that recomWell HPV16/18/45 ELISA kit could 
be used in research to assess quantitatively the expression of HPV16 E7. The E7 ELISA results 
















Figure 20. Quantification of HPV16 E7 protein expression by ELISA.  In this assay 6× 103 (A), 2× 
103 (B), and 0.7× 103 (C) cells were used for each experimental group. For detection of E7 in 
recombinant viruses, Fi301 cells were left uninfected (Mock) or infected with HCMV (MOI 1). 
Afterwards, cells were collected after 48 p.i. The same cell number was also used for pcDNAE6/E7Kpn-
I U251 cells. The absorbances detected for experimental probes were expressed relative to the 
absorbance measured for the positive control (the same number of CaSki cells). Bars represent the mean 
of three in dependent experiments ± SEM. 
3.3.2 Optimized HCMV-based vaccines expressing HPV16 E6-derived peptide 
3.3.2.1 Construction of HCMV-based vaccines with C-terminus fusion of HPV16 E6-
derived peptide 
In order to investigate the optimum peptide presentation using HCMV-based therapeutic 
vaccines, the HLA-A2‐binding peptide E629-38 (TIHDIILECV) derived from the E6 protein of 
HPV16 [265] was fused with a double Alanine (AA-) linker (AATIHDIILECV) to the C-
terminus of HCMV proteins such as  IE1 or UL83. These regions were selected because they 
have consistent expression and strong T cell recognition in lytic infection, and they have an 
inflationary response in latency [14, 125]. 
This peptide (TIHDIILECV) was chosen as we have an established immunological assay to 
analyze presentation by TCR-based testing. This allows us to validate our strategy in the 
development of HCMV-based vaccines (see Section 3.3.4). 
Insertion of E6-derived peptide was carried out by En passant mutagenesis (see Section 2.2.2.6). 
the DNA-encoding sequence for this peptide was already included in the mutagenesis primers, 
that is why no shuttle plasmids were needed to generate the PCR fragments for mutagenesis. 
For this purpose, three viruses were constructed. The RVTB40ΔUS11 was utilized to construct 





terminus of IE1 (using primers E6PepIE1F and R); the generated BAC was named 
RVTB40ΔUS11_E6peptideIE1-BAC. In the other one, the same peptide was fused to C-
terminus of UL83 using primers E6PepUL83F and R, and the generated BAC was named as 
RVTB40ΔUS11_E6peptideUL83-BAC (Figure 21). 
Another BAC (RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1-BAC) was generated by 
fusing the E6-drived peptide to C-terminus of IE1 in RVTB40ΔUS11_E6/E7intoUL83; which 
had been generated on the background RVTB40ΔUS11-BAC (see Section 3.3.1.1). However, 
this virus is deficient for UL83 which is considered as an immunodominant protein and also 










Figure 21. Construction of HCMV-based vaccines expressing E6-derived peptide. The HPV16-E6 
peptide (underlined) with AA- linker was fused to C-terminus of HCMV proteins. (A)  
RVTB40ΔUS11_E6peptideIE1-BAC with E6 peptide fused to UL123 (IE1). (B) 
RVTB40ΔUS11_E6peptideUL83-BAC with E6 peptide fused to UL83 (pp65). (C) 
RVTB40ΔUS11_E6/E7intoUL83 _E6peptideIE1-BAC with E6/E7 sequence replaced UL83(pp65) and 
E6 peptide fused to UL123 (IE1). 
To confirm the construction of recombinant HCMV-based vaccines, PCR with primers flanking 
the target site was carried out (Figure 22) and the amplified fragments from final mutants were 





















Figure 22. PCR for HCMV-based vaccine expressing E6-derived peptide. PCR was carried out 
using primers flanking the target regions. (A) PCR using primers SeqIE1F and R, showing the insertion 
of HPV16 E6-derived peptide with kanamycin cassette (RVTB40ΔUS11_E6peptideIE1 kan-BAC) and 
the resolution of kanamycin to get the final mutant (RVTB40ΔUS11_E6peptideIE1-BAC). (B) PCR 
using primers SeqUL83C-terF and R and the bands show the construction of the intermediate mutant 
with kanamycin (RVTB40ΔUS11_E6peptideUL83fusion kan-BAC) and the resolution of kanamycin 
cassette (RVTB40ΔUS11_E6peptideUL83-BAC). The 100 bp DNA ladder (Thermo Scientific) was 
used (M). The amplified DNA fragments from the final mutants were sequenced using the same primers 
(data not shown). 
3.3.2.2 Growth kinetics of HCMV-based vaccines C-terminus fusion of HPV16 E6-derived 
peptide 
Multi-step growth kinetics were carried out for all peptide-expressing viruses in Fi301 cells. 
The experiment was carried as previously described for E6/E7-expressing viruses (see Section 





Figure 23. Growth curve kinetics of HCMV-based vaccines with C-terminus fusion of HPV16 E6-
derived peptide. Fi301 cells were infected at MOI of 0.01. Supernatant was collected at different time 
points after infection and titrated on Fi301 cells to calculate the TCID50. Results are derived from three 
independent experiments; error bars represent the mean ± SEM. Results were analyzed using Two-way 
ANOVA and there was no significant difference among the growth curves (P value 0.9807). 
3.3.3 Immunopeptidome analysis of HCMV-based vaccines 
In order to investigate the heterogenous antigens presentation of HCMV-based vaccines, we 
analyzed the peptides processed and presented by MHC-I and MHC-II molecules as previously 
described (see Section 2.2.4.6). To gain insight into this, Fi301 cells were left uninfected or 
infected with HCMV-based vaccine candidates (RVTB40ΔUS11_EF-1E6/E7 and 

















































Figure 24. Overview of the identified peptides upon HCMV-based vaccine infection. The number 
of the derived peptides for MHC-I (I) and MHC-II (II) were analyzed by mass spectroscopy. Fi301 cells 
were left uninfected (Mock) or infected with RVTB40ΔUS11_EF-1E6/E7 (A) or 
RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1 (B). The bars represent the mean of three technical 
replicates. 
Interestingly, the HCMV-derived MHC-I peptides of Fi301 cell were much higher in number 
upon infection with RVTB40ΔUS11_EF-1E6/E7 than 
RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1. However, in both cases no HPV16 peptides 
could be detected. The identified viral peptides were analyzed as previously described (see 






allele rank Gene name 
QYDPVAALF P06725 A2402 UL83 (pp65) 
LLIDPTSGLLGA P16789 A0201 UL98 
TLINGVWVV P09717 A0201 US16 
GLLAHIPAL P09717 A0201 US16 
YPRPPGSGL P16757 B0702 UL16 
ALFNQLVFTA P16812 A0201 UL34 
FQIGHTDSV P16812 A0201 UL34 
TILDKILNV P16729 A0201 Major capsid protein 
LYILLPTEL P09728 C0702 US10 
QYAEGLRQL P16725 C0702 UL76 
LLINTGITV P69334 A0201 US18 
YLLEQIQNL P16732 A0201 Tripartite terminase subunit 3 
YVLDPDIVGV P09700 A0201 US24 
AYEYVDYLF P06473 A2402 gB 
ALFSFGVQV P09729 A0201 US9 





SPRFSSPAEF P17147 B0702 Major DNA-binding protein 
SLYADPFFL P16736 A0201 DNA replication helicase 
TRLFLSHVEV P16736 B2705 DNA replication helicase 
VYSPVVESL P16781 A2402 UL43 
LLDDVPPHV Q7M6R1 A0201 UL21A 
FTDNVRFSV P16724 A0201 Tripartite terminase subunit 1 
LYSTNFLTL P16849 A2402 UL33 
RLLDLTQMV P16784 A0201 UL47 






allele rank Gene name 
VLAELVKQI P13202 A0201 UL123 (IE1) 
YPRPPGSGL P16757 B0702 UL16 
LYILLPTEL P09728 C0702 US10 
VYLPKDAFF P16753 A2402 UL80 
LLIDPTSGLLGA P16789 A0201 UL98 
LLINTGITV P69334 A0201 US18 
SRLKLVLSF P16776 B2705 UL5 
Table 22. Immunopeptidomic analysis of HCMV-based vaccines of infected Fi301 cells. HPV16 
E6- or E7-derived peptides were not detected from infected Fi301 cells with RVTB40ΔUS11_EF-
1E6/E7 or RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1.  
3.3.4 Immunological assays 
In order to establish the platform for HCMV-based vaccine development, two different 
immunological assays were carried out based on specific TCR stimulation for HLA-A2 
peptides (E629–38: TIHDIILECV and pp65495-503: NLVPMVATV). Infection of Fi301 cells and 
stimulation of PBMCs transduced with specific TCRs could simulate the eventual clinical 
application of these vaccines for treatment of HPV16-induced cancer. Furthermore, infection 
of GBM cells with these vaccines could show whether these vaccines would be useful for the 
treatment of GBM by delivering neoantigens (such as E6 and pp65 peptides) which could render 
these tumor-driving cells vulnerable to cytotoxic attack by specific CTLs. 
3.3.4.1 IFN-γ release in response to E6 and pp65 peptide for Fi301 infected with HCMV-
based vaccines 
Human PBMCs isolated, as previously described (see Section 2.2.3.5), were transduced with 
either retroviral vector encoding E6-specific TCR (pMP71-PRE-E6) or retroviral vector 
encoding pp65-specific TCR (MP71TCRα and MP71TCRβ) as previously described (see 
Section 2.2.6.2). Untransduced PBMCs were included as a negative control and treated in the 
same way. In order to analyze the T cell stimulation, IFN-γ was measured as previously 





corresponding E6-derived or pp65-derived peptides were also co-cultured with the transduced 
PBMCs as a positive control to give the maximum stimulation for IFN-γ release. Although 
infected Fi301 with E6/E7 expressing HCMV mutants could stimulate specific T cells for pp65 
(except for RVTB40ΔUS11_E6/E7intoUL83 that lacks pp65), none of HCMV-based vaccines 
expressing E6/E7 protein could stimulate E6-specific T cells. Only RVTB40ΔUS11_EF-
1E6/E7-infectd Fi301 showed slight stimulation for E6-specific T cells (Figure 25).  
Interestingly, all HCMV-based vaccines expressing HPV16 E6-derived peptide could strongly 
stimulate E6-specific T cells for IFN-γ release. Moreover, all of them could also stimulate pp65-
specific T cells for IFN-γ release, except for RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1 




























Figure 25 Release of IFN- by TCR transduced PBMCs after stimulation with infected cells. 1x105 
human PBMCs, transduced with HPV E6-specific TCR and HCMV pp65-specific TCR, respectively, 
or non-transduced (Background), were co-cultured for 16 hours with 1x105 Fi301 cells that had been 
infected for 48 hours with HCMV-based vaccines. PBMCs as described above were also co-cultured 
with infected Fi301 cells that had been additionally pulsed with the corresponding peptide (maximal 
peptide stimulation). Subsequently, IFN- production was measured by ELISA. Release of IFN- is 
shown as percentage of maximal peptide stimulation after subtraction of the background. Uninfected 
cells (Mock) and cells infected with RVTB40ΔUS11 (Control) were also included in this type of 
analysis.  Results are derived from three experiments; error bars represent the mean ± SEM; n.d., not 
detectable.  
3.3.4.2 Stimulation of transduced Jurkat cell with specific TCRs 
Three HLA‐A2 GBM cell lines were included in this study to analyze the role of HCMV-based 
vaccine in rendering the GBM susceptible for recognition and attack by specific CTLs. As 
previously described (see Section 2.2.4.4), the cell lines (U343, LN18 and U251) were infected 
with HCMV-based vaccines at MOI 5 and reporter Jurkat cell lines were used as a read out of 
T cell activation.  
3.3.4.2.1 Detection of NF-κB activation upon Jurkat cell line stimulation 
Jurkat cell line (Jurkat E6-1) with EGFP expression under the control of NF-κB [261] was 
transduced with retroviral vector encoding HLA-A2‐restricted HPV E629-36-specific TCR or 
with retroviral vector encoding the HCMV-specific TCR recognizing an HLA-A2‐restricted 
epitope derived from pp65 (pp65495-503) as previously described (see Section 2.2.6.2). All 
HCMV-based vaccines expressing pp65 showed pp65-specific Jurkat cells stimulation, 





vaccines expressing the E6-derived peptide in fusion to viral protein could significantly 











Figure 26. NF-B-driven EGFP expression in reporter cell lines stimulated by infected GBM cells. 
5x104 GBM cells (LN18, U343 or U251 cells) were infected with HCMV-based vaccines (MOI of 5). 
After 2 days and 4 days, respectively, infected cells were co-cultured with HPV E6-specific reporter 
cells (left graphs) and HCMV pp65-specific reporter cells (right graphs), respectively, for 24 hours at a 
ratio 2:1. Subsequently, EGFP expression of reporter cells was determined by FACS analysis. 
Uninfected cells (Mock) and cells infected with RVTB40ΔUS11 (Control) were also included in this 
type of analysis. Stimulation of reporter cells is given as percentage of maximal peptide stimulation, i.e. 
stimulation of reporter cells incubated with peptide pulsed cells. Results are derived from three technical 
replicates; error bars represent the mean ± SEM. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 





3.3.4.2.2 Detection of NFAT activation upon Jurkat cell line stimulation 
The J76 cell with NFAT-driven EGFP [259] was transduced with a retroviral vector encoding 
HLA-A2‐restricted HPV E629-36-specific TCR (pMP71-PRE-E6) or HLA-A2‐restricted HCMV 
pp65495-503-specific TCR (MP71TCRα and MP71TCRβ) [259] as previously described (see 
Section 2.2.6.2). Infected GBM cell lines were infected and handled as described for NF-κB 
assay (see Section 3.3.4.2.1). 
Although the detection of NFAT activation was less sensitive than NF-κB [258], similar results 
were obtained. Only HCMV-based vaccine expressing E6-derived peptide fused to viral protein 





Figure 27. NFAT-driven EGFP expression in reporter cell lines stimulated by infected GBM cells. 
5x10 4 GBM cells (LN18, U343 or U251 cells) were infected with HCMV-based vaccines (MOI of 5). 
After 2 days and 4 days, respectively, infected cells were co-cultured with HPV E6-specific reporter 
cells (left graphs) and HCMV pp65-specific reporter cells (right graphs), respectively, for 24 hours at a 
ratio 2:1. Subsequently, EGFP expression of reporter cells was determined by FACS analysis. 
Uninfected cells (Mock) and cells infected with RVTB40ΔUS11 (Control) were also included in this 
type of analysis. Stimulation of reporter cells is given as percentage of maximal peptide stimulation, i.e. 
stimulation of reporter cells incubated with peptide pulsed cells. Results are derived from three technical 
replicates; error bars represent the mean ± SEM. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 





3.3.4.2.3 A novel HCMV-encoded block of MHC-I presentation 
The GBM-infected cells with E6/E7-expressing recombinant HCMV vaccine candidate failed 
to stimulate E6-specific T cells despite abundant E6/E7 protein expression was surprising.  To 
investigate this mechanism, aliquots of pcDNAE6/E7Kpn-I U251cells, which stably express 
the E6/E7 protein, were left uninfected or RVTB40ΔUS11-infected at different MOIs with the 
HCMV-vector. Thereafter, cells were acid washed as described previously (see Section 
2.2.6.5). Subsequently, cells were co-cultured with HPV E629-36-specific reporter cells, which 
express EGFP under the control of NF-κB responsive elements [263]. Figure 28 shows that 
pcDNAE6/E7Kpn-I U251 cells (positive control) but not untransfected U251 cells (negative 
control) stimulated E6 peptide-specific reporter cells. Interestingly, acid washed 
pcDNAE6/E7Kpn-I U251 cells that had been infected with different MOIs of the HCMV-
vector showed a significantly reduced capacity to stimulate E6-specific reporter cells as 
compared to acid washed uninfected pcDNAE6/E7Kpn-I U251 cells (Figure 28). After 
additional pulsing with exogenous E6 peptide, however, acid washed pcDNAE6/E7Kpn-I U251 
cells that had been infected could stimulate E6-specific reporter cells to a similar extent as acid 
washed uninfected pcDNAE6/E7Kpn-I U251 cells (Figure 28). Strikingly, the block of MHC-
I antigen presentation induced by the HCMV-vector was more than 50% (Figure 28).  Taken 
































Figure 28.  Block of MHC-I presentation induced by immune evasions-deficient HCMV. U251 
cells stably expressing the E6/E7 protein (pcDNAE6/E7Kpn-I U251 cells) were left uninfected or 
infected with RVTB40ΔUS11, a mutant HCMV lacking all known viral MHC-I blockers, at the 
indicated MOIs for 3 to 24 hours. Subsequently, cells were harvested, washed with PBS and 
subsequently washed with ice-cold citric acid, to remove all preexisting peptide-MHC complexes 
and co-cultured at a ratio of 2:1 with HPV E6-specific reporter cells, in which NF-κB drives EGFP. 
After 18 hours EGFP expression was assessed by FACS analysis. Unwashed U251 cells (Negative 
control) and unwashed pcDNAE6/E7Kpn-I U251 cells (Positive control) were also co-cultured with 
HPV E6-specific reporter cells. In parallel, maximal peptide stimulation was determined for each 
experimental group by pulsing cells additionally with E6 peptide (1 µg/ml) before co-culture with HPV 
E6-specific reporter cells and subsequent FACs analysis. (A) The stimulation in each experimental 
group is given as percentage of maximal peptide stimulation. (B) The % of EGFP+ reporter cells after 
pulsing with E6 peptide (maximal peptide stimulation) is shown for washed pcDNAE6/E7Kpn-I 
U251 cells left uninfected and washed pcDNAE6/E7Kpn-I U251 cells infected with mutant HCMV 
at the indicated MOIs. (C). The block of MHC class I presentation after infection with mutant HCMV 
at the indicated MOIs is given as a percentage. The results shown are derived from three independent 







4.1 Optimization of HCMV for vaccine vector construction 
The ability of CMV to elicit and maintain high frequencies of effector memory CTLs, makes 
CMV-based vectors promising to develop novel prophylactic and therapeutic vaccines against 
infectious diseases as well as cancer [266]. This study initially aimed to generate an optimized 
HCMV vector that can be eventually used as a platform for generating therapeutic vaccines that 
induce strong CTL-mediated immunity against a target antigen derived from a pathogen or 
tumor.  
4.1.1 RL13 and UL128 mutations are crucial for HCMV reconstitution and virus 
propagation in fibroblasts 
The most promising HCMV strains for the generation of vaccine vectors should be able to infect 
DCs and establish latency in vivo in order to elicit and maintain potent memory inflation. 
Simultaneously, these vectors should be safe and amenable to the genetic modifications 
essential for the insertion of heterologous antigens [266].  
The circular mini-F BAC plasmids allow HCMV or other herpesviruses genomes to be stably 
maintained at low copy number and manipulated in E. coli and then reconstituted as infectious 
virus by transfection of eukaryotic cells [267]. So far, most HCMV research is based on the 
laboratory strains, i.e. AD169 and Towne, which have major disadvantages [268]. It has been 
reported, that these HCMV strains show many mutations due to extensive passaging in 
fibroblasts. The main genomic regions affected are the RL13 and UL128 locus [245, 269]. 
These mutations can limit the ability to infect endothelial cells and DCs and hence restrict the 
memory inflation of CTLs [264]. With this in mind, the BAC of the clinical HCMV strain 
Merlin was selected initially to generate the vaccine vector. Merlin was derived from the urine 
of a congenitally infected infant and sequenced after 3 passages in human fibroblasts [245, 270]. 
During the construction of Merlin strain BAC, mutations that affect HCMV coding regions 
were repaired by mutagenesis and recombineering. The virus recovered from BACs by DNA 
transfection harbors only a residue of single loxP and NheI sites (40 bp) located between US28 
and US29. However, the presence of this sequence does not show any effect on the expression 
of the flanking genes [245]. 
The HCMV Merlin BAC (RCMV1161-BAC), which had been repaired for both RL13 and 





either from sequential mutations in the same template or as a result of recombination between 
independent mutants [245]. Several mutants were constructed using RCMV1161-BAC to delete 
all MHC-I downregulating genes (US2, US3, US6, and US11). However, none of these mutants 
could be reconstituted and propagated in fibroblasts. These findings were in accordance with a 
previous study showing that RL13 and UL128 restrict either HCMV cell-to-cell transmission 
or production of cell-free virus in fibroblasts [245].   
4.1.2 Deletion of HCMV-encoded MHC-I downregulating genes improves antigen 
presentation 
The failure to reconstitute RCMV1161-BAC prompted us to use HCMV TB40/E strain which 
combines the high endothelial cell and DCs tropism of a clinical isolate with the high titer 
growth of a cell culture adapted strain [23, 271]. Interestingly, the mini-F sequence of the 
corresponding BAC (TB40-BAC4) was inserted into to the viral genome, replacing the US2-
US6 region [271]. In a previous study, DCs infected with RVTB40/EΔUS11 stimulated T cells 
to produce more IFN-γ than DCs infected with TB40/E WT although both infected DCs equally 
well [272].  
Although HCMV strain TB40/E also shows mutations in both RL13 and UL128L these stable 
mutations did not prevent the virus from being propagated in fibroblasts while retaining 
epithelial cell tropism [268, 273]. These results suggested that TB40-BAC4 is well suited for 
generation of vaccine vectors. For further optimization, the US11 gene was deleted and the 
BAC generated (RVTB40ΔUS11-BAC) was successfully reconstituted in fibroblasts. Although 
US11-deleted HCMV has been generated previously [272], we aimed to generate this mutant 
in our laboratory and to characterize it for further clinical applications. The resulting mutant 
lacks US2-6 and US11, which account for the MHC-I downregulation observed in HCMV-
infected cells. However, a previous study showed that these genes do not alter the expression 
levels of other immunologically relevant molecules such as MHC-II, CD40, CD80, CD86 and 
CD83 [272]. Although fibroblasts infection by TB40/E WT downregulate MHC-I molecules, 
the analysis of MHC-I expression in RVTB40ΔUS11-infected Fi301 cells showed that the 
downregulation effect mediated by US2, US3, US6, and US11 was abolished upon deletion of 
these genes.   
The HCMV mutant RVTB40ΔUS11 could replicate in fibroblasts and showed growth kinetics 
similar to TB40/E WT. This finding demonstrates that US2-6 and US11 are not essential for 
viral reconstitution and propagation in cell culture and further confirm the findings of the 





The CMV-encoded MHC-I downregulating genes could totally abrogate the development of 
specific CTL response against heterogenous antigens in rhesus macaques using RhCMV-based 
vaccines against Ebola [162]. However, this can be also due to another CMV-encoded block of 
MHC-I antigen presentation (see Section 4.2.1).   
4.2 Construction of HCMV-based vaccine against HPV16-induced cancer 
It is estimated that HPV-related cancers account for 7-8 % of all human cancers [181]. Although 
several prophylactic vaccines against HPV have been generated and are being used worldwide 
[274], there is no approved therapeutic vaccine against HPV-induced cancer [275]. In the last 
few years, several immunotherapeutic approaches have been explored, however, therapeutic 
vaccines are very promising as a treatment option for HPV-induced cancer [276]. In this work, 
we decided to generate a therapeutic vaccine against HPV-induced cancer using our optimized 
HCMV vector (RVTB40ΔUS11). 
4.2.1 HCMV-based vaccine expressing E6/E7 protein does not present peptides derived 
from E6/E7  
As a DNA virus, HPV is relatively stable [277]. Only a limited number of genotypes are 
implicated in HPV-induced cancers, HPV16 being the most prevalent [278, 279]. HPV-encoded 
E6 and E7 are the main conserved oncogenes responsible for cell transformation and 
carcinogenesis. After HPV-induced cell transformation, the cancer express HPV-derived E6 
and E7 oncogenes that are both of low diversity, making them ideal targets for immunotherapy. 
[280, 281]. A fused DNA consensus sequence encoding non-transforming fusion protein of 
HPV16 E6/E7 that covers all relevant antigenic peptides was synthesized following the 
published sequence [282]. In a previous study, the mice vaccinated with this DNA vaccine 
encoding this fused protein showed both CD4+ T cells and CTL responses against the encoded 
antigens with prophylactic and therapeutic effects [282]. 
Several HCMV BACs encoding the E6/E7 protein were constructed during this study. 
However, only four of them could reconstitute virus and were thus examined further. The 
resulting HCMV-based vaccines differ in the expression characteristics of E6/E7 protein due 
to different promoter activities that drive E6/E7 expression. For example, the 
RVTB40E6/E7intoUS11 and RVTB40ΔUS11_EF-1E6/E7 mutants, expressed high level of 
E6/E7 protein under the control of endogenous and exogenous promoters, respectively. Some 
other major immune evasion genes where interrupted or deleted in other vaccine candidates, 





The HCMV RVTB40_E6/E7intoUS11 mutant shows a minimal change to the parent 
RVTB40ΔUS11 genome by replacing US11 with the E6/E7 sequence. This virus can express 
the E6/E7 protein under the control of the US11 promoter, which is activated in the early phase 
of infection [283]. In fact, several mammalian promoters are commonly used in cell culture to 
generate stable and potent expression of genes. One of these promoters, the EF‐1α promoter, is 
constitutively active in a broad range of cell types [284, 285]. Moreover, several studies showed 
that EF‐1α promoter is more resistant to silencing than other viral promoters [286-288]. The 
HCMV RVTB40ΔUS11_EF-1E6/E7 mutant was constructed to express E6 and E7 under the 
control of exogenous promoter EF-1 α [286-288]. Our results showed that the TB40-BAC4 can 
tolerate insertion of large DNA fragments up to 2200 bp (the EF‐1α promoter and fused E6/E7 
genes) with successful reconstitution of these modified BACs. 
During HCMV latency, only a subset of viral genes are transcriptionally active [109, 289-292], 
including HCMV UL111A (cmvIL-10), which encodes a protein that is a homolog of the potent 
immunomodulatory cytokine hIL-10. UL111A is transcriptionally active during both 
productive and latent HCMV infection and encodes several viral IL-10 proteins according to 
alternative splicing of the transcribed RNA [107, 109, 110, 116]. UL111A-encoded protein 
mediates different immunomodulatory functions that support viral latency, including inhibition 
of cytokine synthesis, MHC-I molecule modulation in infected cells, suppression of B cell 
stimulation during latency, and hindering DCs maturation and cytotrophoblast function [112, 
117, 293, 294]. It has been shown that cmvIL-10 expression during viral latency in primary 
human myeloid progenitor cells is implicated in modulation of MHC-II levels which results in 
inefficient recognition of the infected cells by allogeneic or autologous CD4+ T cells [117]. 
The HCMV RVTB40ΔUS11_E6/E7intoUL111A mutant was generated through insertion of 
the E6/E7 sequence in frame with the second exon, making it translationally active in both lytic 
and latency phases [116, 295].  
HCMV UL83-encoded protein (pp65) is one of the most abundant tegument proteins, however 
it is not essential for viral growth and production of infectious virions in vitro [296].  Moreover, 
it is implicated in several immunomodulatory features in infected individuals that counteract 
both innate and adaptive immune responses against HCMV infection [54, 297, 298]. We have 
successfully generated a pp65-deficient vaccine candidate, RVTB40ΔUS11_E6/E7intoUL83. 
In this mutant, UL83 was replaced in frame by the E6/E7 sequence. UL83 has an early-late 





immune evasion action by blocking antigen presentation [21, 298], modulating NK cells 
functions [299] and supressing several antiviral cytokines [300-302].  
For HPV16 infection diagnosis, previous studies have shown that western blot (WB) as well as 
ELISA can be used [303]. However, WB of E6 and E7 proteins showed either a low sensitivity 
or specificity when compared to other diagnostic tools such as Hybrid Capture 2 (HC2) test and 
ThinPrep cytological test (TCT), respectively [304].  In this study, the expression of both 
HPV16 E6 and E7 was analyzed for all recombinant viruses after the infection of Fi301 cells. 
In addition, these tests were used to determine expression of the E6/E7 protein in stably 
transfected cells with E6/E7 protein expression plasmid (pcDNAE6/E7Kpn-I U251 cells) as a 
positive control. Our results showed that all these mutant viruses can express the E6/E7 protein 
with different expression levels. As shown in results, the recomWell HPV16/18/45 ELISA kit 
can be used in research to assess quantitatively the expression of HPV16 E7. On the other side, 
OncoE6 Cervical Test™ kit can be used for semi-quantitative detection of HPV16 E6 in 
research assays. Taken together, these assays showed sensitivity to E6 and E7 despite low cell 
numbers and could be a useful tool for in vitro evaluation of HPV16 E6 and E7 protein 
expression.  
Interestingly, none of the fused HPV16 E6/E7-expressing HCMV mutants stimulated Jurkat or 
PBMCs transduced by E629-36-specific TCR. In contrast, all pp65-encoding HCMV mutants 
stimulated pp65495-503-specific TCR transduced Jurkat or PBMCs. As a positive control, 
uninfected pcDNAE6/E7Kpn-I U251 cells stimulated E629-36-specific reporter Jurkat cells. 
In a previous study exploring MCMV-based therapeutic vaccine against HPV-induced cancer, 
it was proposed that the exact position of the immunogenic peptide in the viral protein is crucial 
for peptide processing and presentation [205].  Our results showed that pcDNAE6 /E7Kpn-I 
U251 cells stimulated the specific Jurkat cells while HCMV-expressing the same form of fused 
E6 /E7 did not. We conclude that HCMV impairs presentation of heterologous (recombinant, 
non-HCMV) proteins in a selective way. This mechanism is independent on MHC-I 
downregulation because all MHC-I downregulating genes were deleted from our vector. The 
underlying mechanism, however, is unknown and needs to be researched. We also assume that 
this blocking mechanism is involved in the failure of RhCMV-based vaccine expressing Ebola 






4.2.2 HCMV-based vaccines expressing E6 peptide fused to viral protein stimulate E6-
specific T cells 
In previous studies, MCMV-based vaccines were able to stimulate CTLs against heterologous 
antigens (such as influenza and HPV16 antigens) with the antigenic peptides were fused to viral 
proteins, resulting in protective and therapeutic responses when animals were vaccinated and 
challenged with pathogenic viruses expressing the same antigens [158, 205]. Although these 
vaccine models were based on MCMV, we constructed recombinant HCMV-based vaccines 
using the same strategy.  We generated three HCMV-based vaccines expressing the antigenic 
peptide fused to C-terminus of viral proteins (IE1 and pp65) with a double Alanine (AA-) linker 
that facilitates cleavage and processing of the immunogenic peptide. 
As shown in results, the fusion of the HPV16 E6-derived peptide to the C-terminus of HCMV 
IE1 stimulated specific CTLs to secrete higher levels of IFN-γ than HCMV with peptide fused 
to C-terminus of pp65. However, replacing UL83 with fused E6/E7 protein and fusing the 
HPV16 E6-derived peptide to the C-terminus of IE1 (RVTB40ΔUS11_E6/E7intoUL83 
_E6peptideIE1) did not show better stimulation than by just fusing the HPV16 E6-derived 
peptide to C-terminus of IE1 (RVTB40ΔUS11_E6peptideIE1). We conclude that expressing 
the immunogenic peptide at the C-terminus of HCMV proteins such as IE1 and pp65 is essential 
for efficient MHC-I presentation, and this is not improved by additional expression of the full-
length protein (fused E6/E7). 
We also performed a ligandome analysis for HCMV-infected Fi301 cells with 
RVTB40ΔUS11_EF-1E6/E7 and RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1 mutants, 
which showed several HCMV-derived peptides. However, peptides derived from the E6/E7 
fusion protein were not detected for either mutant viruses although Fi301 cells infected with 
RVTB40ΔUS11_E6/E7intoUL83_E6peptideIE1 stimulated E6-specific T cell. This finding 
demonstrates the higher sensitivity of reporter T cells as compared to detection of mass 
spectrometry, although it could also be that the HPV16 E6-derived peptide (TIHDIILECV), a 
cysteine-containing 10mer peptide, may be difficult to be detected by mass spectrometry. 
4.3 GBM infection by HCMV could be a promising therapeutic option 
GBM is the most aggressive malignant primary brain tumor and is highly lethal with inevitable 
relapse after standard treatment [208]. The current therapeutic options for GBM treatment are 
radiotherapy, chemotherapy (temozolomide), and surgery if possible [221]. However, none of 





15 months after GBM diagnosis [221, 305]. Thus, there is an urgent need to develop novel 
approaches for GBM treatment. 
4.3.1 Virotherapy can be a novel approach for GBM treatment 
One of the novel treatment approaches is the clinical use of oncolytic viruses, which can 
selectively replicate in cancer cells. The results of recent phase I/II clinical trials showed that 
this approach could be highly promising as a treatment option [306, 307]. Virotherapy based 
on utilizing oncolytic replicating virus can induce specific killing of the infected cancer cells. 
Different mechanisms are hypothesized to elucidate killing of cancer cells by these viruses, 
most of these mechanisms are immunogenic [308]. Recently, the use of oncolytic viruses in 
combination with other treatment options such as radiation therapy or chemotherapy has been 
shown to have a synergistic activity [309-311]. This indicates the feasibility of new GBM 
treatment protocols based on the combination of virotherapy with approved forms of GBM 
therapy; especially that GBM and glioma stem–like cells are radio- and chemo-resistant in 
many cases resulting in progression and recurrence of tumor cells. [312, 313]. Interestingly, 
GBM infection by HCMV does not increase the resistance of GBM cells to chemotherapy, 
however, it significantly reduces tumor cell viability [238].  
4.3.2 GBM infection by HCMV produces cell-associated virus rather than free virions 
The detection of HCMV DNA and proteins was associated with GBM in some studies [314, 
315], however, other studies showed contradicting results that HCMV genomes and/or proteins 
were present in neglected proportion in GBM [316-319]. However, GBM cell lines are 
permissive for HCMV which encouraged us to use our generated HCMV-based vaccine as a 
treatment option for GBM.  
The permissiveness of GBM cells to HCMV is not consistent among all cell lines. In a previous 
study using different HCMV strains,  all tested HCMV strains have been shown to infect GBM 
cells [238]. In this study, we chose three different GBM cell lines for further experiments 
(LN18, U343 and U251) due to their expression of HLA-A2 haplotype. This makes it possible 
to analyze the presentation of peptides binding to HLA-A2 by using our T cells recognizing 
E6-peptide in the context of HLA-A2.   
Upon GBM infection with EGFP-expressing TB40/E HCMV at intermediate infection level 
(MOI 0.3), the GBM cells showed different levels of permissiveness and EGFP expression. 





advantageous in our treatment approach, limiting the spread of HCMV to healthy tissues distal 
to the tumor. However, further studies using different MOIs were not done.   
4.3.3 HCMV-based vaccines expressing E6 peptide fused to viral protein render GBM 
cells susceptible for recognition and attack by T cells 
We aimed to use HCMV-based vaccines as an adjuvant for the presentation of high levels of 
vector-encoded neoantigens and repurposing HCMV-specific CTLs to fight the GBM tumors. 
This strategy was supported by our finding that pcDNAE6/E7Kpn-I U251 cells, which were 
stably transfected with E6/E7-expressing plasmid, could stimulate specific TCR-transduced T 
cells. The E6/E7 fusion protein is normally expressed neither in healthy tissue nor in GBM 
cells. After in situ vaccination of GBM with E6/E7-expressing HCMV vaccine, E6/E7 could 
act as a neoantigen that render GBMs susceptible for specific T cell attack. 
We established immunological assays based on Jurkat cells (J E6-1 and J76) that were 
transduced with retroviral vectors encoding TCRs specific for HPV16 E6- or HCMV pp65-
derived peptides. These Jurkat cells were modified for NF-κB or NFAT-driven EGFP 
expression. This assay facilitates the analysis of T cells activation. The cooperation between 
NFAT and NF-κB proteins induces maximal transcription of the IFN-γ gene [320]. Moreover, 
NFAT is required for expression of the cytokine IL-2 [321].  
Our established immunological assays showed that GBM cell lines infected with HCMV-based 
vaccine expressing the entire E6/E7 protein separately from any viral protein did not stimulate 
E6-specific Jurkat cells. They were, however, highly stimulatory for viral pp65-specific Jurkat 
cells when using pp65-encoding viruses. In contrast, GBM cells infected with HCMV-based 
vaccines expressing the HPV16 E6-derived peptide fused to viral proteins could efficiently 
stimulate E6-specific Jurkat cells as well as pp65-specific Jurkat cells (with the exception of 
mutant HCMV lacking pp65). These results are in accordance with our finding of TCR-
transduced PBMCs stimulation and confirm that fusing the antigenic peptides derived from 
heterologous proteins to the C-terminus of HCMV proteins (such as IE1 and pp65) is highly 
efficient for processing and presentation of the non-HCMV antigenic peptides. 
In conclusion, HCMV-based therapeutic vaccines are very promising as a novel therapeutic 
approach for GBM and HPV-induced cancer therapy.  Further studies using animal models are 
recommended to investigate the therapeutic potential of our vaccines. More studies are needed 
for constructing other recombinant HCMV-based vaccines based on our prototype to develop 





group are exploring the attenuated HCMV-based vaccines to undergo one only round of 
infection. In addition, we are currently investigating the mechanism underlying HCMV-










Human papilloma virus (HPV), which belongs to the most common sexually transmitted human 
pathogens, is linked to several cancers including cervical and oropharyngeal cancer. The most 
important HPV genotypes in this respect are HPV16 and HPV18.  Expression of the highly 
conserved HPV-encoded E6 and E7 oncoproteins is required for the initiation and progression 
of HPV-associated malignancies. So far, no approved therapeutic vaccine against HPV-
associated cancer is available. Another important type of cancer is glioblastoma multiforme 
(GBM), the most aggressive primary brain tumor. GBM patients have a very short median 
survival time despite standard treatment involving surgery, chemotherapy, and radiation. Thus, 
novel therapeutic strategies are urgently needed to improve the poor prognosis of GBM patients.  
The aim of this study was to develop a human cytomegalovirus (HCMV)-based platform for 
generation of therapeutic vaccines against cancer. Malignant cells are killed by cytotoxic CD8+ 
T lymphocytes (CTLs) that recognize tumor neoantigens presented by MHC class I molecules 
(MHC-I). Thus, therapeutic cancer vaccines should induce a high frequency of CTLs that can 
recognize tumor neoantigens. In this regard, HCMV is a very promising starting point for a 
vaccine platform. HCMV, a member of the β-herpesvirinae affecting 60-80% of the population 
in the developed countries, causes latent asymptomatic infection in immunocompetent 
individuals. The persistent HCMV infection is associated with a uniquely high frequency of 
HCMV-specific CTLs with an effector-memory phenotype representing 10-20% of all 
circulating T cells, a phenomenon called memory inflation. Accordingly, a tumor neoantigen 
vectored by HCMV should induce strong antitumor responses. As a proof of principle, we 
developed a HCMV based therapeutic vaccine that can induce CTLs recognizing HPV16-
encoded E6 as a neoantigen. Intriguingly, these HCMV-based vaccines can also infect GBM 
cells. This finding paves the way for altering the immunogenicity of GBM by driving the 
presentation of E6 as a neoantigen, thus rendering GBM susceptible to CTL attack, e.g. after 
adoptive transfer of E6-specific autologous T cells.  
In order to optimize antigen presentation to CTLs, HCMV-encoded MHC-I downregulating 
genes (US2-US11) were deleted in the HCMV vector. This modified vector was used to express 
a non-transforming HPV16 E6/E7 fusion protein that covers all the relevant antigenic peptides. 
Further HCMV modifications such as insertion of exogenous promoter or interruption of 
additional immune evasion genes (such as UL111A) were introduced to optimize the CTL 
response. In addition, different types of HCMV-based vaccine candidates were constructed by 





only the latter could efficiently stimulate E6 peptide-specific T cells. To explore the mechanism 
that interferes with processing and presentation of the HPV16 E6/E7 fusion protein, cells were 
stably transfected with a plasmid expressing the HPV16 E6/E7 fusion protein. Intriguingly, 
these E6/E7 expressing cells were able to stimulate E6 specific T cells in the absence of HCMV. 
However, this stimulation was significantly inhibited when E6/E7-expressing cells were 
additionally infected with HCMV, although the HCMV used no longer possessed any MHC-I-
downregulating genes. This finding shows a novel HCMV-encoded block of MHC-I antigen 
presentation that is independent of the already known MHC-I downregulating HCMV genes. 
This is the first study describing the construction of HCMV-based vaccines expressing tumor 
neoepitopes and provides the preclinical basis for development of HCMV-based therapeutic 
vaccines against cancers. Further investigations using different cell lines in vitro as well as in 


















Das humane Papillomvirus (HPV), welches zu den häufigsten sexuell übertragbaren 
menschlichen Krankheitserreger gehört, ist mit verschiedenen Krebsarten einschließlich 
Cervixkarzinom und Oropharynxkarzinom assoziiert. Die wichtigsten HPV-Genotypen in 
dieser Hinsicht sind HPV16 und HPV18.  Die Expression der hochkonservierten HPV-
kodierten E6- und E7-Onkoproteine ist für die Initiierung und das Fortschreiten von HPV-
assoziierten Malignomen erforderlich. Bislang ist kein zugelassener therapeutischer Impfstoff 
gegen HPV-assoziierten Krebs verfügbar. Eine weitere wichtige Krebsart ist das Glioblastoma 
multiforme (GBM), der aggressivste primäre Hirntumor. GBM-Patienten haben trotz der 
Standardbehandlung mit Operation, Chemotherapie und Bestrahlung eine sehr kurze mediane 
Überlebenszeit. Daher werden dringend neue therapeutische Strategien benötigt, um die 
schlechte Prognose von GBM-Patienten zu verbessern.  
Das Ziel dieser Studie war die Entwicklung einer auf dem humanen Cytomegalievirus (HCMV) 
basierenden Plattform für die Herstellung therapeutischer Impfstoffe gegen Krebs. Bösartige 
Zellen werden von zytotoxischen CD8+ T-Lymphozyten (CTLs), die von MHC-Klasse-I-
Molekülen (MHC-I) präsentierte Tumor-Neoantigene erkennen, abgetötet. Daher sollten 
therapeutische Krebsimpfstoffe eine hohe Frequenz von CTLs induzieren, die Tumor-
Neoantigene erkennen können. In dieser Hinsicht ist das HCMV ein sehr vielversprechender 
Ausgangspunkt für eine Impfstoffplattform. HCMV, ein Mitglied der β-Herpesvirinae, das 60-
80% der Bevölkerung in den entwickelten Ländern betrifft, verursacht eine latente 
asymptomatische Infektion bei immunkompetenten Personen. Die persistierende HCMV-
Infektion ist mit einer einzigartig hohen Frequenz von HCMV-spezifischen CTLs mit einem 
Effektor-Gedächtnis-Phänotyp verbunden, der 10-20% aller zirkulierenden T-Zellen ausmacht, 
ein Phänomen, das als „Memory inflation“ bezeichnet wird. Dementsprechend sollte ein durch 
HCMV exprimiertes Tumor-Neoantigen starke Immunreaktionen gegen den Tumor auslösen. 
Als „Proof of principle“ haben wir einen therapeutischen Impfstoff auf der Basis von HCMV 
entwickelt, der CTLs induzieren kann, die HPV16-kodiertes E6 als Neoantigen erkennen. 
Interessanterweise können diese Impfstoffe auf HCMV-Basis auch GBM-Zellen infizieren. 
Diese Erkenntnis ebnet den Weg für eine Veränderung der Immunogenität von GBM, indem 
sie die Präsentation von E6 als Neoantigen ermöglicht und damit GBM anfällig für einen CTL-




Um die Antigenpräsentation für CTLs zu optimieren, wurden HCMV-kodierte MHC-I 
herunterregulierende Gene (US2-US11) im HCMV-Vektor deletiert. Dieser modifizierte 
Vektor wurde zur Expression eines nicht-transformierenden HPV16 E6/E7-Fusionsproteins 
verwendet, das alle relevanten antigenen Peptide abdeckt. Weitere HCMV-Modifikationen wie 
die Einfügung eines exogenen Promotors oder die Unterbrechung zusätzlicher 
Immunevasionsgene (wie UL111A) wurden eingeführt, um die CTL-Antwort zu optimieren. 
Darüber hinaus wurden andere Impfstoffkandidaten auf HCMV-Basis konstruiert, die ein 
dominantes antigenes Peptid des HPV E6 Proteins verknüpft mit HCMV-Proteinen 
exprimieren. Überraschenderweise weise konnten nur letztere effizient E6-Peptid-spezifische 
T-Zellen stimulieren. Um den Mechanismus zu untersuchen, der die Prozessierung und 
Präsentation des HPV16 E6/E7-Fusionsproteins stört, wurden Zellen stabil mit einem Plasmid 
transfiziert, welches das HPV16 E6/E7-Fusionsprotein exprimiert. Interessanterweise konnten 
diese E6/E7-exprimierenden Zellen E6-spezifische T-Zellen stimulieren – in Abwesenheit von 
HCMV. Diese Stimulation wurde jedoch bei einer zusätzlichen Infektion E6/E7-
exprimierenden Zellen mit HCMV signifikant gehemmt, obwohl das verwendete HCMV keine 
MHCI-herunterregulierenden Genen mehr besaß. Dieser Befund zeigt einen neuartigen 
HCMV-kodierten Block der MHC-I-Antigenpräsentation, der unabhängig von den bereits 
bekannten MHC-I herunterregulierenden HCMV-Genen ist. 
Dies ist die erste Studie, welche die Herstellung von Tumor-Neoepitop exprimierenden 
HCMV-basierten Impfstoffen beschreibt. Sie ist damit die präklinische Grundlage für die 
Entwicklung von therapeutischen Impfstoffen gegen Krebs auf HCMV-Basis. Weitere 
Untersuchungen mit verschiedenen Zelllinien in vitro und in vivo, die die Sicherheit und die 
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